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ABSTRACT 
Osteosarcoma (OS) is the most common primary bone tumor in dogs and it accounts for 
nearly 10% of all diagnosed canine cancers. Despite aggressive multimodality therapy, the 
mortality rate for canine OS exceeds 90% from the development of distant metastases to lungs 
and other visceral organs. Given the high metastatic rate and associated mortality, there is a 
compelling rationale to explore novel therapeutic approaches that may slow the progression or 
inhibit the development of distant metastases. 
Successful metastasis requires cytoskeletal morphogenic changes of tumor cells, allowing 
for efficient and directional cell migration. Cell motility requires coordinated cytoskeletal 
rearrangement largely controlled by Rho GTPase proteins (RhoA, RhoC, Rac-1 and Cdc42) and 
effector pathways (Rho-kinase; ROCK). Given their pivotal role in directional cell migration, 
perturbing the function of Rho GTPases is considered a viable anti-metastasis strategy. 
Disruption of Rho GTPase functions can be achieved by interfering with protein prenylation, a 
pivotal post-translational modification necessary for Rho GTPase subcellular localization and 
protein-protein interactions. 
Zoledronate (ZOL) is a potent antiresorptive agent that definitively reduces the frequency 
and severity of malignant skeletal complications in people. As an antiresorptive agent, ZOL 
exerts its biologic effects on osteoclasts by inhibiting the mevalonate pathway which is necessary 
for protein prenylation. Although a large body of scientific information exists characterizing its 
anticancer effects within the local bone tumor microenvironment, ZOL’s potential antimetastatic 
properties remain less well defined. Despite several different murine tumor models describing 
ZOL’s capacity to reduce visceral metastases, a unifying molecular mechanism for these 
observations has yet to be reported. We hypothesized that ZOL will impair Rho GTPase 
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prenylation and activity, with subsequent perturbation of the cell cytoskeleton and motility in OS 
cells, and serve as the molecular basis for ZOL’s observed antimetastatic effects. 
The effects of ZOL on K7M2 murine OS cells were investigated by characterizing 
perturbations in 1) membrane and cytosolic Rho GTPases and phosphorylated myosin light chain 
2 (p-MLC2) by western blot analysis; 2) cytoskeletal structure with confocal fluorescence 
microscopy; 3) migration by qualitative and quantitative analyses; and 4) metastases 
development ex vivo and in vivo using an experimental lung metastasis model. 
 The results of this study were that exposure to ZOL decreased membrane-bound Rho 
GTPases with concurrent accumulation of unprenylated Rho GTPases within the cytosol, 
reduced expression of p-MLC2, attenuated the expression of focal adhesions and filamentous 
actin, and inhibited in vitro cell migration. Ex vivo single cell videomicroscopy also showed that 
ZOL can significantly decrease early pulmonary nodule formation. Lastly, ZOL treatment 
induced a significant increase in survival of mice from OS lung nodules; however, this 
improvement was modest and was achieved only with pre-treatment of tumor cells in vitro. 
Findings from this investigation document the prenylation-dependent effects of ZOL on 
Rho GTPases and their impact on OS cell cytoskeletal organization, migration, survival, 
proliferation, and metastases formation. These observations provide a foundational basis for 
evaluating adjuvant ZOL for managing micrometastatic disease in dogs with spontaneously-
arising OS. 
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CHAPTER 1 
INTRODUCTION 
Tumor metastasis, one of the six hallmarks of cancer, is considered one of the most 
challenging aspects of cancer management, and remains responsible for most cancer-associated 
deaths [1]. The course and factors determining the progression of tumor metastasis are not yet 
fully understood, and further research is necessary to define the steps undertaken by tumor cells 
during this process and to develop treatment strategies that will limit their success. Many 
theories were developed to describe tumor metastasis, the earliest one being the “seed and soil 
hypothesis” which was followed by the “progression model”. The most recent theories predict 
the presence of cancer stem cells that have migration capabilities (migrating cancer stem cells; 
MCS cells) as the ones responsible for tumor metastasis, explaining the recapitulation of all 
features of the primary tumor by distant growths [2, 3]. 
Tumor cell dissemination and metastasis depends upon successful fulfillment of all steps 
described in “The Metastatic Cascade” [4]. Despite daily shedding of millions of tumor cells 
from the primary tumor, the formation of tumors at secondary sites occurs at a relatively low 
frequency; a concept termed ‘metastatic inefficiency’ [5, 6]. In-depth research of the events 
taking place during metastasis has led to the realization that some of the steps in the cascade are 
very efficient, while others are highly inefficient. The early steps leading to tumor cell 
intravasation and extravasation at the secondary site are considered to be highly efficient and not 
rate limiting for metastasis. This is supported by the identification of abundant individual tumor 
cells within circulation that successfully arrive and arrest within secondary organs [7, 8]. In 
contrast, various experimental tumor models and imaging techniques, including high resolution 
in vivo video-microscopy studies and quantitative cell-fate analysis, document that a large 
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proportion of the cells able to survive the early steps of extravasation and arrival at the future 
metastatic site are unable to persist and establish their colonies, with only a small number of cells 
able to form micrometastatic lesions [9-11]. This may suggest that the most rate-limiting steps in 
metastasis occur after individual cell extravasation and that these limit or dictate the absolute 
success of metastases development. As such, investigational anti-metastatic therapies which 
perturb these highly inefficient steps, specifically, treatments that can inhibit directional cell 
migration and invasion post extravasation, would most likely exert a great therapeutic benefit. 
Many of the aspects related to cell motility and directional migration involve proteins 
from the family of Rho GTPases. Of this family, RhoA, RhoC, Rac1 and Cdc42 are the ones best 
studied due to their important role in metastasis [12]. The activation/inactivation of these 
proteins is dependent upon GTP/GDP exchange, and once active, Rho GTPases allow 
recruitment of various effectors that in turn activate multiple signaling cascades necessary for 
cell motility and other cell functions [13]. ROCK I and ROCK II are direct effectors of RhoA 
and RhoC [14], and their activity is important for the contractility of actomyosin fibers; ROCK 
increases the levels of phosphorylated myosin light chain (p-MLC) directly by its kinase 
properties and indirectly by phosphorylation and inactivation of myosin phosphatase [15, 16]. 
The functionality of Rho GTPases is also dependent upon their subcellular localization and 
maximum activity occurs after anchorage within the inner leaflet of the plasma membrane, which 
is achieved by protein prenylation [17]. Both in vitro and in vivo studies show that inhibition of 
Rho GTPases’ activity or blockade of Rho effectors are both effective for inhibition of metastasis 
[18-24]. Because subcellular localization of Rho GTPases to the inner leaflet of the plasma 
membrane is critical for Rho GTPase activity and subsequent activation of downstream effector 
pathways (ROCK I and II), drugs which interfere with the prenylation of Rho GTPases may 
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perturb cell motility enough to make the inefficient process of post-extravasation metastasis even 
more inefficient. 
Zoledronate (ZOL) is a potent, commercially-available, nitrogen-containing 
bisphosphonate used as a first-line agent for managing malignant osteolysis associated with 
skeletal carcinoma metastases (breast, prostate, and lung) and multiple myeloma [25, 26]. In 
addition, ZOL has been demonstrated to be safe and effective for the management of focal 
malignant osteolysis in dogs diagnosed with OSA [27]. Although the clinical indication for ZOL 
is to reduce malignant skeletal osteolysis via the reduction in osteoclast numbers and activity, it 
has been postulated that ZOL may exert antimetastatic effects through the inhibition of the small 
GTPase protein prenylation via inhibition of the mevalonate pathway. This postulation has been 
supported in some, but not all studies, whereby the administration of ZOL in mouse models of 
OSA and breast cancer reduced the extent of visceral organ and pulmonary metastases [28-31]. 
Although these preclinical studies demonstrate ZOL’s potential antimetastatic effect, a unifying 
molecular mechanism for these preclinical observations has yet to be reported. 
Based on this information we hypothesized that ZOL impairs Rho GTPase prenylation, 
with subsequent perturbation of downstream effector pathways, cytoskeletal rearrangement, and 
motility. In attempt to define a possible impact of ZOL on OS metastasis and to clarify its 
mechanism of action, we have decided to test our hypothesis on the highly metastatic murine 
K7M2 OS cell line. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1. Tumor metastasis 
2.1.1. Introduction to metastasis in cancer diseases 
 Tumor metastasis is one of the most clinically challenging and research intriguing areas 
within the field of oncology. It is defined as the dissemination of tumor cells from a primary 
cancer site to a distant organ, where tumor cells successfully give rise to new cancer colonies, 
and is also described as being one of the six hallmarks of cancer [1]. With cancer being a 
worldwide leading cause for death in people, accounting for 7.4 million (approximately 13%) of 
all deaths in 2004 [32], and being estimated as the cause for 90% of cancer deaths [1], metastasis 
is a major cause of mortality within the population of cancer patients. Being the culmination of 
neoplastic progression, the finding of tumor metastasis carries with it a poor prognosis and low 
survival rates regardless the type of tumor. The American Cancer Society has reported in 2007 
on the statistics of cancer, showing a significant difference in the 5-year survival of patients 
diagnosed with localized disease compared to those diagnosed with distant metastasis [33]. For 
example, the 5-year survival rate for localized skin melanoma is 99% while it decreases to 15% 
in the presence of distant spread of disease. Similar findings were reported for tumors of other 
body organs, such as the colon and prostate, with 5-year survival rates of 49% and 90% 
respectively for local disease, compared with 2% and 10% respectively for distant disease [33]. 
Comparable outcome patterns were reported for numerous other tumors including breast [34, 
35], lung [36], and gastric cancer [37]. 
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Still, even with these significant differences in survival rates between patients with and 
without cancer dissemination, many of the cancer patients not showing signs of distant 
metastasis at first presentation are at risk for late development of tumor spread. This 
phenomenon, also called tumor dormancy, is commonly noted in women with sentinel lymph 
node-negative breast cancer [38]. Although, free of disease 5 years after definitive treatment, 15-
25% of these women were still at risk for distant progression of tumor [38]. Similarly, there was 
an 18% cumulative probability to develop metastasis of salivary gland cancer 15 years after 
diagnosis [39] and in a cohort of locally invasive melanoma patients approximately 13% 
developed distant metastasis ≥ 8 years after initial diagnosis [40]. Hence, the course and 
determinants for tumor progression and metastasis are not fully understood, and thus, with 
metastasis having such a devastating and significant effect on survival, it is clearly important to 
find tools for early cancer detection and treatment. Even more so, it would be extremely valuable 
to fully unravel the mechanisms that govern the process of tumor metastasis as these may help 
with architecting therapeutic agents to inhibit cancer spread. 
 
2.1.2. Overview of metastasis hypotheses and models 
 Despite exponential growth in the research of cancer metastasis in the past 30 years it is 
still difficult to explain the evolution of this process. This is due to the complexity of the 
metastatic cascade, the different patterns of tumor cell dissemination in various neoplastic 
diseases, the capacity for metastatic tumor cells to become dormant at distant sites, and the 
complex interaction of tumor cells with the microenvironment in which they reside. Therefore, it 
is not surprising to find the existence of many models to explain the mechanisms that enable 
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metastasis to occur. For the same reasons, it is clear why none of the currently available models 
yet succeeds in fully explaining all features of tumor metastasis. 
 
2.1.2.1. Historical models of metastasis: “seed and soil” vs. “mechanical entrapment” 
 Maybe the earliest of all metastasis theories is the “seed and soil hypothesis” made 
by Stephen Paget [41]. This hypothesis is based on a series of 735 fatal breast cancer patients 
analyzed by the author, in which a non-random pattern of metastatic dissemination was 
observed. The pattern of secondary tumors was repeatable in such a frequency that it could not 
be explained by random embolism of cells from the primary tumor. This has led Paget to 
conclude that certain organs are predisposed for secondary cancer as they provide a congenial 
“soil” for the tumor cells (the “seeds”). 
Another early theory that contrasted the “seed and soil hypothesis” was published by 
James Ewing in 1929 [42]. In his theory of “mechanical entrapment” Ewing proposed that the 
pattern of tumor cell dissemination is solely dictated by mechanical factors related to the 
anatomy of body organs and their vascular flow pattern. Since tumor cells are often larger than 
the diameter of small capillaries they are bound to get trapped in the first vascular bed that drains 
the primary tumor from which these cells originated [42]. Over the past 40 years it has been well 
demonstrated that both theories hold truth and that a combination of these two probably most 
closely illustrates the events that take place during metastasis. In 1979, Sugarbaker has reviewed 
cancer metastasis in length and discussed the factors that govern the pattern of tumor cell spread 
[43]. It was concluded in this article that vascular and lymphatic physiology highly contributes to 
implantation of tumor cells, but at the same time, a large variety of cellular characteristics and 
complex tumor-host interactions are involved in specifying the location of distant tumor nodules. 
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2.1.2.2. Modern era models: The “progression model” vs. “dynamic heterogeneity model” 
 The development of advanced research and experimental tools has allowed the 
accumulation of a large body of data used to generate models attempting to explain the 
biological complexities of tumor metastasis (reviewed in [44, 45]). One of the most commonly 
accepted theories of metastasis over the past 3 decades is detailed in the “progression model”. 
Initially proposed by Nowell [46] and shortly after by Fidler & Kripke [47], this model states 
that the majority of tumors originate from one cell, which goes through a variety of genetic 
modifications that allow for selection of more aggressive cell subclones. The pressure of genetic 
selection together with microenvironmental pressure on the tumor cells produces variants with 
progressively different genotypes, and this parallels with the biological characteristics of tumor 
progression (i.e., loss of differentiation, invasion, metastasis, and resistance to therapy) [46]. 
Two main issues of metastasis were left unexplained with the “tumor progression 
model”. The first is the presence of tumors of unknown primary origin [48]; this clinically 
evidenced tumor entity goes against the concept of clonal tumor evolution arising from the bulk 
of a primary tumor. The second inconsistency is the observation of an ability of some highly 
metastatic tumor cell clones to regress back to a low metastatic capability [49]. This was 
observed after testing the metastatic capability of parental and subclones of two sarcoma cell 
lines (KHT-24 and KHT-35) by injecting them intravenously to mice and then analyzing the 
number of lung nodules that were formed. Unexpectedly, it was found that there were major 
differences in the lung tumor-forming ability between the parental clones and the subclones they 
had initiated in culture; when compared to the parental clones, all subclones from one cell line 
showed a marked decrease in nodule formation while 2 out of 7 subclones in the other cell line 
showed a higher metastatic ability [49]. It was concluded that a high rate of random and 
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stochastic epigenetic and/or genetic mechanisms are responsible for this variance in metastatic 
ability, leading to a heterogeneous tumor cell population with effective metastatic cells 
comprising only a small fraction of it. 
The results of this study has led the research group of Harris et al. to propose a model for 
tumor metastasis termed “dynamic heterogeneity” [50], and later on this model was expanded by 
Weiss et al. and was called “the transient compartment model” [51]. The latter theorized that the 
changes allowing cells to become metastatic include random genetic mutations and also 
microenvironmentally-induced epigenetic changes and vascular accessibility factors, and that 
these allow only a small proportion of the cells to gain full metastatic capability at any given 
moment in time [51]. But once again, this theory contradicts one of the main hallmarks of 
cancer, namely clonal origin. If all tumor cells within a heterogeneous population of a primary 
tumor have the inherent ability to become metastatic then there wouldn’t have been such 
homogeneity in the identity of cells from metastatic lesions within one patient, as it is usually 
found. 
 
2.1.2.3. The “fusion model” and “gene transfer model” 
 Another model for metastasis suggests that tumor cells gain this unique ability to 
spread by acquiring the characteristics of lymphoid cells (reviewed in [52]). This model, termed 
the “fusion model”, is based upon evidence that shows spontaneous hybridization between tumor 
cells and bone marrow-derived cells in animals. It is proposed that this fusion, caused by a still 
unknown mechanism, allows for the aneuploidy and heterogeneity found in tumors, which confer 
the cell an ability to express diverse features arising from both parental cells, such as 
angiogenesis, cell-matrix changes, motility, chemotaxis and immune signaling pathways [52]. 
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Another relatively similar model is the “gene transfer model”, also known as the 
“genometastasis hypothesis” [53], which suggest that cancer cells from a primary tumor may 
supply the oncogenic stimuli to cells in the distant organ in the form of free DNA particles. 
These DNA fragments, that contain dominant oncogenic sequences, arrive at the distant site by 
plasma circulation, transfect susceptible cells and cause transformation [53]. By large, these two 
lastly presented models have not gained much acceptance. The fusion model has been criticized 
for relying mostly on in vitro fusion of cells with only sparse evidence for occurrence of these 
events in vivo. The genometastasis model is unable to support the clear organ tropism pattern 
shown for various tumors. Also, it seems unlikely for a DNA fusion to occur in such 
repeatability that would lead to a large number of homogenous tumor nodules, such that are 
commonly evidenced in cancer patients. 
 
2.1.2.4. The “early oncogenesis model” challenges the “progression model” 
 The application of DNA microarray analysis on tumor samples over the past decade 
has been the basis for one of the recent models developed for metastasis termed “early 
oncogenesis”. One of the most significant discoveries, made by van’t Veer at al by using this 
form of analysis, was the 70-gene signature derived from breast cancer tissues predictive of 
distant metastasis and poor prognosis in lymph node-negative breast cancer patients [54]. It was 
found that patients expressing genes of the ‘signature’ had a 15-fold odds ratio to develop 
metastasis within 5 years of diagnosis, compared to patients with a negative signature that were 
still disease-free at that time. The genes included in this ‘signature’ included ones that are 
necessary for cell cycle control, invasion, metastasis and angiogenesis. Based on this data the 
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researchers have concluded that the potential for metastasis is already programmed in cells that 
were transformed early in initiation of the primary tumor [54]. 
The conclusion made about the metastatic trait being early-embedded in the cells of the 
primary tumor challenges the concept presented by the prevailing “progression model”: the 
hypothesis that rare tumor cells subjected to metastasis-promoting mutations within an enlarging 
primary tumor are the cause for the devastating cancer spread [55]. But indeed, the “early 
oncogenesis model” has been supported by substantial evidence. Findings similar to ones made 
by  van ‘t Veer et al. [54] were published using the same gene profile on a different population of 
breast cancer patients [56, 57], using a different microarray platform on breast cancer tumors 
[58], and in a variety of solid tumors, including lung, prostate, and breast adenocarcinoma, and 
medulloblastoma [59]. Another convincing piece of evidence to support this model is the result 
of a study by Hüsemann et al. who showed the presence of disseminating (mammary) tumor cells 
(DTCs) in the bone marrow of HER-2 and PyMT transgenic mice and of women with breast 
cancer already at the pre-invasive stage of tumor progression [60]. The DTCs found in these 
women were shown to have no chromosomal aberrations/instability, such that was found in the 
primary tumor, suggesting for their early dissemination before stroma invasion [60]. The ‘early 
oncogenesis model’ also supplies an explanation for metastasis of tumors of unknown primary 
origin; an entity the ‘progression model’ fails to explain. With all tumor cells having the 
potential to spread early during the formation of the primary tumor, it is easier to foresee how 
multiple distant nodules may arise synchronously while having similar size, appearance and 
progression as of the initial mass. 
Still, the “early oncogenesis model” has its own imperfections. First, it should be 
acknowledged that DNA microarray analysis of a whole tissue is reporting the averages of gene 
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expression in a large population of cells [61, 62]. Hence it might not detect rare variant pre-
metastatic cells potentially having a different gene signature. Second, if all tumor cells have the 
ability to form metastatic lesions it would be expected that a much larger proportion of tumor 
types than is currently evidenced would culminate with metastasis. 
The gap between the two main concepts for metastasis has been analyzed and discussed 
in a number of articles [44, 61, 63-65], and a few approaches have arisen to reconcile the 
argument. The first approach tries to solve an inherent problem of the “early oncogenesis model” 
that not only the effects of somatic mutations may have an impact on the expression of genes but 
also inherited genetic polymorphism [44]. Thus, it was hypothesized that gene expression 
predictive signatures may be affected by each individual’s inherited susceptibility for metastasis. 
Indeed, an example of this exists in a study by Park et al. which identified polymorphism in the 
signal transduction gene Sipa1 in mice [66]. The expression levels of this gene, encoding for a 
Rap1 GTPase activating protein (GAP), were found to have a significant impact on formation of 
lung nodules in experimental metastasis of a highly aggressive mouse mammary tumor cell line. 
High expression levels of Sipa1 also correlated with metastatic progression in human prostate 
cancer [66]. Since then, there have been other reports of polymorphic genes with a specific role 
in tumor metastasis and metastatic efficiency [67-71]. These findings have led to a combined 
theory: the susceptibility for cancer is determined at an early stage by gene expression patterns, 
which is contributed by each individual’s genetic polymorphism. As a tumor evolves it acquires 
somatic mutations, as hypothesized by the “progression model”, and these allow for obtaining 
the ability to complete the metastatic cascade [44]. 
Following a different approach to analysis of this conceptual problem, Kang et al. 
suggested another variation to the model of early oncogenesis [72]. In their experiments they 
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investigated the properties that allow the typical formation of osteolytic bone metastasis by 
MDA-MB-231, a human breast cancer cell line, in a mouse model. After a second round of 
injection of tumor cells from a metastatic bone lesion to mice, it was found that the cells have 
segregated into two subpopulations that differed from the parental cells; one that had high bone 
metastasis potential and another that was adrenal-oriented [72]. Analyzing these populations with 
a DNA microarray, it was found that, similar to the parental cells, all cells had a 70-gene poor 
prognosis signature. Evaluation of single cell expansions from the parental cell line, it was 
noticed that cells with bone metastasis capability had expression of a unique set of genes 
including, interleukin (IL)-11, connective tissue growth factor (CTGF), chemokine (C-X-C 
motif) receptor-4 (CXCR-4), matrix metalloproteinase-1 (MMP-1), and osteopontin (OPN). 
Cells expressing four of these five genes were highly bone metastatic in vivo but ones not 
expressing these genes did not produce bone lesions [72]. This has led to propose that as 
previously identified, all cells of primary tumors with metastatic capability have a poor-
prognosis signature. However, in addition, subpopulations of cells from the primary tumor have 
a superimposed tissue-specific gene-expression profile that controls the site of tumor spread 
(Figure 2.1). 
 
2.1.2.5. Cancer stem cells in tumor self-renewal and metastasis 
 The most recent theory, gaining acceptance over the past few years in the field of 
cancer metastasis and cancer in general, is that of cancer stem cells (CSCs) being the main 
contributors for the self-renewal capacity of tumors and the very early cells from which tumors 
originate. The theory of CSCs proposes that tumor cells are organized in a hierarchical fashion, 
much like normal tissues are organized. Cancer stem cells are positioned at the top of the 
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hierarchy and by means of asymmetrical cell divisions they give rise to two different cell 
populations: one is that of identical self-renewing stem cells and the other is that of transit 
amplifying cells that then give rise to the more differentiated population of cells within a tumor 
[73-75]. The presence of CSCs has been initially discovered in the hematopoietic cancers acute 
myeloid leukemia [76] and chronic myelogenous leukemia [77], but has since been shown to 
exist in a large variety of solid tumors, including breast, colon, pancreas, lung, prostate, 
melanoma and glioblastoma (reviewed in [78]). Notably, in all these cases, the implicated cells 
were found to constitute only a very small fraction of the primary tumor mass, as it would be 
expected from stem cells. They are also identified by the expression of a unique constellation of 
cell surface markers, such as CD44, CD90 or CD133, and these cells display significant 
tumorigenic capacity, recapitulating the morphologic and immunohistologic characteristics of the 
primary tumor, even when injected at relatively low numbers to immune-compromised mice 
(compared with injection of high numbers of tumor cells negative for the specific CSC markers 
resulting in no tumorigenesis). 
The theory of CSCs has also made many important contributions to the understanding of 
tumor metastasis as there is accumulating evidence to suggest that these unique cells are not only 
responsible for the self-renewal and maintenance of the primary tumor but also for the successful 
colonization and formation of macrometastases at distant sites [79, 80]. This concept was 
originally made after the observation of the tumor dormancy phenomenon, suggesting that 
cancer initiation occurs in slowly-, but continuously, dividing immortal CSCs. In a process that 
takes months to years these cells allow the promotion of cancer to occur, including the formation 
of distant metastasis [81]. Specific evidence for the presence of metastatic CSCs were available 
from analysis of tissue samples of breast cancer patients which revealed bone marrow DTCs with 
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a putative phenotype of stem cells already in an early stage of the disease [82]. So far, there is 
direct evidence that proves the metastatic capability of cancer stem cells in human pancreatic 
adenocarcinoma [2], small cell and non-small cell lung carcinoma [83], and hepatocellular 
carcinoma [84]. Interestingly, metastatic pancreatic CSCs were found positive not only for 
CD133 stem cell marker but also for CXCR4 receptor, a receptor that has a key role in regulation 
of invasiveness and specific trafficking of metastatic cells to distant tissues, such as lung, bone 
marrow, liver, and lymph nodes [2]. Elimination of CD133
+
 CXCR4
+
 tumor cells has completely 
abrogated the process of tumor metastasis without affecting the tumorigenicity of the cells and 
blockade of CXCR4 receptor with a specific antibody had a similar effect [2]. This is indicative 
of the significant importance of the interaction between the cancer (stem) cells and the tumor 
microenvironment (or pre-metastatic niche) for successful tumor spread. Also of importance is 
the finding of CD133
+
 CXCR4
+
 CSCs mostly at the invasive front of the tumor, and very rarely 
in the bulk of the pancreatic tumor, where differentiated tumor cells were localized, suggestive of 
the role of these CSCs in dissemination from the periphery of the primary tumor [2]. 
Further studies and accumulating evidence have led a few research groups to incorporate 
the theory of CSCs in their models for tumor metastasis. For example, in colorectal cancer 
progression there were found a few markers that link between CSCs and metastasis, including β-
catenin and Wnt-targets L1 cell adhesion molecule (L1CAM) and γ2-chain of laminin (LAMC2) 
[3]. All of these markers, specific for epithelial-mesenchymal transition (EMT) of disseminating 
cancer cells, were found to be transiently expressed and activated in tumor cells at the tumor-host 
interface [3]. This has led Brabletz et al. to propose the ‘migrating cancer stem (MCS)-cell’ 
model as one that integrates and consists all aspects of human tumor progression. In this model, 
the invasive front of the tumor is pictured as the ‘germ-cell layer’ of radially MCS cells (Figure 
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2.2). These cells asymmetrically divide to produce other stem cells but also differentiated tumor 
cells that make the bulk of the tumor. It was hypothesized that the main difference between the 
primary tumor and metastases is the distance of migration of MCS cells; short-distance MCS 
cells only contribute to the mass of the primary tumor and ones able to invade blood/lymph 
vessels migrate to long distances and make metastases [3]. A somewhat similar model was 
proposed for breast cancer metastasis by Weigelt et al. (Figure 2.3). Here, both the “progression 
model” and the concept of “early oncogenesis” were adopted, stating that metastatic ability can 
be distinguished by the 70-gene expression profile, determined by mutations that occur in cancer 
stem cells and supported by stromal fibroblasts [35]. Mutations in a differentiated progenitor cell 
may give rise to a good-prognosis, non-metastatic breast carcinoma. However, oncogenic 
transformation of an early breast cancer stem cell may cause accumulation of mutations and lead 
to a ‘poor-prognosis carcinoma’. These CSCs may also express specific markers that localize 
them to different distant sites [35]. 
Importantly, the incorporation of CSCs into models of tumor spread helps to explain 
many of the features of cancer diseases and solves all or most of the controversies that exist 
between the different hypotheses for metastasis. First, the presence of CSCs stands in agreement 
with the “seed and soil hypothesis”: a CSC (the “seed”) circulates in blood/lymph vessels and 
seeks for an appropriate “soil” from which it receives appropriate microenvironmental cues. 
Once found, the new microenvironment stimulates the growth of the CSC and its genetic 
phenotype drives the differentiation of a metastasis in correspondence with the features of the 
primary tumor [75]. Secondly, the ability of CSCs to go through an asymmetric cell division 
enables the formation of a wide variety of genotypically- and phenotypically-different tumor 
cells, which fits perfectly with the paradigm of tumor cellular heterogeneity originating from a 
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monoclonal cell population [79]. The CSCs theory also very easily explains the common 
occurrence of tumor drug resistance and disease relapse even after complete surgical removal of 
the primary tumor and chemotherapy treatment, as CSCs have been shown to express multidrug 
resistance (MDR) transporters, which allows for tumor repopulation from a minimal residual 
disease (reviewed in [85]). Lastly, it was also demonstrated that CSCs from a variety of tumors 
have the ability to reactivate their telomerase enzyme, leading for another mechanism to explain 
their immortal nature [86]. 
Obviously, there is much more to discover before a unified theory for tumor metastasis 
will be possible. Importantly, there is much that is yet to be learned about the transient 
mechanisms that allow the mobility of metastatic cancer (stem) cells, an important feature that 
lies in the center of the metastatic cascade. It is also of utmost importance to better define the 
contribution of the microenvironment to the establishment of metastases. However, it is clear 
that CSCs are becoming a more visible target and that a complete solution for cancer metastasis 
must involve CSCs-directed therapy. 
 
2.1.3. The metastatic cascade 
 The process of tumor cell dissemination and outgrowth has been summarized under 
what is termed “The Metastatic Cascade”, a cascade of sequential and interrelated events that 
need to take place for the successful formation of a distant tumor nodule [44, 45, 87-90]. By 
convention, metastasis requires the ability of a tumor cell to (1) disseminate through epithelial-
mesenchymal transition (EMT), (2) invade and migrate through the extracellular matrix (ECM), 
(3) intravasate into blood/lymph vessels, (4) survive circulatory transport in blood/lymph vessels, 
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(5) extravasate into distant target organs, (6) establish a metastatic niche, and (7) grow and form 
tumor nodules [4, 44, 87, 88] (Figure 2.4). 
 
2.1.3.1. Epithelial-mesenchymal transition 
 In order for tumor cells to metastasize they must first detach from the bulk of the 
primary tumor and breach the basement membrane that surrounds the abnormally proliferating 
tissue. This process has traditionally been described for epithelial tumors, as these comprise the 
majority of human cancers and were initially under more intense investigation [91]. During this 
process epithelial tumor cells lose their adhesion to surrounding epithelial cells, lose apical-basal 
cell polarity, and gain mesenchymal characteristics that include motility, invasiveness, inhibition 
of apoptosis, and promotion of anchorage independent growth [92-94]. There are numerous 
pathways and proteins known to induce EMT in both normal embryonic development and cancer 
diseases (Figure 2.5) [92], but perhaps one of the most commonly described event in cancer 
spread is the loss of E-cadherin adhesion molecule expression [91, 95]. This prototypic type I 
cadherin mediates homophilic cellular interactions by connecting to extracellular 
immunoglobulin (Ig) domains and by linking these to cytoplasmic actin filaments through β-
catenin and α-catenin molecules. Loss of E-cadherin may occur through genetic/epigenetic 
mutations, and transcriptional repression, all of which have been correlated with the acquirement 
of mesenchymal features and increased tumorigenesis [92]. Of importance, signaling through E-
cadherin has a direct impact not only on cell-cell adhesion but also on the cytoskeletal stability 
and formation of actin stress fibers and migratory membrane protrusions such as lamellipodia 
and filopodia [96]. 
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Important in EMT is also the specific repertoire of integrins expressed on the surface of the cell 
that make contact with the extracellular matrix (ECM). Like cadherins, integrin molecules have a 
dual function; they serve both to regulate cell adhesion to its surrounding microenvironment and 
as signaling molecules that link between the ECM and the actin cytoskeleton [97, 98]. Notably, 
specific combinations of integrins such as αvβ3, α3β1 and others are predominantly linked with 
enhanced cell invasion and metastasis in various cancer types [1, 99, 100]. A vital player in 
integrin-mediated EMT signal transduction pathways and integrin-cytoskeleton linkage is 
integrin-linked kinase (ILK) [101]. This kinase localizes to focal adhesions of the cell and its 
expression/dysregulation has been implicated as a poor prognostic factor in a variety of human 
tumors [102-106]. Multiple signaling molecules have been found activated downstream of 
integrins, including FAK, Src-family kinases, glycogen synthase-kinase-3 β (GSK3 β) and 
protein kinase B (PKB/Akt), and these impact not only cell invasion/migration but also cell 
survival and proliferation [98]. 
Once detached from its surrounding cells and ECM the tumor cell may degrade the 
nearby matrix to facilitate its migration. This feature is achieved by membrane-bound and 
secreted matrix metalloproteinases (MMPs) [107]. There is evidence that shows the 
accumulation of MMPs (MT1-MMP, MMP-2, and MMP-9) in actin-rich membrane protrusions 
called invadopodia, structures commonly found in invading tumor cells [108, 109]. Of the MMPs 
known, MMP-3, -7, and -9 were found to assist in cell motility by targeting and cleavage of E-
cadherin-mediated cell-cell adhesion [110-112]. Some MMPs were also shown to interact with 
cell-ECM adhesion molecules. For example, active MT1-MMP and MMP-2 were found to co-
localize with αvβ3 integrin [113, 114], and this was found to facilitate matrix degradation and 
invasion of cultured melanoma cells [114]. Other cell adhesion molecules were also found as a 
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specific target for active MMPs. For example, CD44 was found to concentrate the activity of 
MMP-9 in colorectal and mammary carcinoma cells [115, 116], and CD147 assists in tumor cell 
invasion by activating MMP-1, -2, -3, and -9 [117]. 
Other than adhesion molecules and matrix metalloproteinases, there is a wide array of 
pathways and mediators that were well investigated and described to be involved in EMT. For 
example, TGF-β signaling pathway functions as a master regulator in this trans-differentiation 
process (reviewed in [118]), playing a role in delocalization, degradation and downregulation of 
cell-cell junctions. EMT is also tightly regulated by transcriptional factors, among which are 
included Notch [119], Twist [120], NF-kappaB [121], and ZEB and snail factors [122]. 
Important for the study presented here is the pivotal role of Rho GTPases in determining the 
balance between epithelial and mesenchymal cell morphology (reviewed in [123]) as well their 
part in the complex regulation of apoptosis inhibition that takes place after detachment of the 
tumor cell from its ECM (i.e. anoikis) (see 2.2.4.1 and 2.2.4.2). 
 
2.1.3.2. Invasion and migration 
 Tumor cells that have freed themselves from their neighboring cells and from their 
immediate ECM have to now gain motility capabilities in order to successfully invade tissues 
and blood/lymph vessels. This activity is viewed as a spatially and temporally integrated process 
organized by specific groups of proteins and through constant cytoskeletal rearrangement [124, 
125]. Motile cells have been described as going through a “Migration Cycle” (Figure 2.6) [14] in 
which cells first undergo polarization in response to an extracellular stimulus. This determines 
the repertoire of molecules that will concentrate at the front or sides/rear of the cell to exert their 
activity. The Rho GTPases Cdc42 and Rac were found to be greatly involved in this initial step 
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by defining the site of formation of cell protrusions [126] and also by reorganizing and localizing 
the microtubule-organizing center (MTOC), a structure important for microtubule growth and 
supplementation of proteins needed for forward protrusion [127]. Other molecules important for 
cell polarization are phosphoinositide 3-kinases (PI3Ks) and PTEN (phosphatase); these control 
levels of phosphinositides PIP2 and PIP3 which serve to amplify small chemoattractant gradients 
faced by the cell and to maintain positive feedback loops for activity of Cdc42 and Rac GTPases 
[126, 128, 129]. 
Following polarization the cell undergoes a stage of protrusion and adhesion formation, 
making actin-based protrusions directed towards a migratory-promoting signal. The main 
structures described being engaged in cell protrusion for attachment and adhesion includes 
lamellipodia and filopodia [130, 131]. These elements each have a different organization pattern 
of actin filaments dictating them to appear as broad, flat, sheet-like structures called 
lamellipodia, or thin, cylindrical, needle-like projections called filopodia (Figure 2.7). The 
formation of these elements is made by different patterns of actin polymerization, forming 
branching, dendritic-like filaments for lamellipodia, and long parallel actin bundles for filopodia. 
The protrusive capability of these structures is also driven through different mechanisms at the 
leading edge; lamellipodia protrude using an “elastic Brownian ratchet” mechanism where 
thermal energy bends short filaments during their polymerization and this stored energy is used 
to push the membrane out once unbending an elongated filament [132]; filopodia protrude using 
a filament treadmilling mechanism in which actin filaments are polymerized at the barbed edge 
of an actin bundle pointed towards the cell membrane and supported by other molecules to 
provide the stiffness necessary for pushing the cell membrane [133]. As in the polarization stage, 
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members of the Rho GTPase family proteins were found crucial for these protrusive events as 
well [134]. 
Adhesion of the cell is made possible via stabilization and attachment of protrusive 
elements to ECM molecules through integrin receptors. Integrins interact with the actin 
cytoskeleton via adaptor proteins like α-actinin, vinculin, talin, and filamin, and make local 
clusters that form structures called focal adhesions (FAs) [135]. The formation of FAs is induced 
by a variety of intracellular signaling pathways including activity of focal adhesion kinase 
(FAK), PI3K, protein kinase C (PKC) and Rho GTPases; this makes an ‘inside-out’ signaling via 
integrins [136-138].  Integrins also activate ‘outside-in’ signaling by recruitment of the above 
mentioned adaptor proteins and other signaling molecules that induce phosphorylation and 
dephosphorylation signals into the cell [136]. The connection made by integrins between the 
ECM and the cytoskeleton of the cell has a dual role; it serves both as a traction site for the cell 
to move over, as well as a mechanosensor of the ECM structure that may prompt changes in the 
cytoskeleton arrangement [124, 139]. 
Finally, for completion of the cycle, the cell retracts the trailing edge, disassembles 
adhesions to ECM and undergoes rear retraction. The main mechanism for cell contraction is 
produced by the attachment and movement of myosin II molecules over filamentous actin 
bundles called actin stress fibers (Figure 2.7) [140]. These are the product of actin filament 
polymerization that takes place in parallel with formation of FAs and makes elongated 
cytoplasmic bundles of actin. Myosin II activity is tightly regulated by activating and inhibiting 
molecules. Activation is governed by myosin light chain (MLC) after its phosphorylation by 
Ca
2+
- and calmodulin-dependent myosin light chain kinase (MLCK) [15]. On the other hand, 
MLC activity is counteracted by MLC phosphatase, thereby inhibiting myosin II activity [141]. 
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Another important player in actomyosin contraction is Rho-kinase (ROCK); once activated by 
Rho GTPase activity, ROCK can inhibit MLC phosphatase and hence maintain cell contraction 
[115, 117]. Actin-bound myosin II units (also called actomyosin), can then exert contraction 
forces, conducting tension towards adhesion sites and pulling forward the trailing edge of the 
cell. During that time there is also a continuous cycle of adhesion disassembly/formation at the 
leading edge coupled with formation of new protrusions, and disassembly of adhesions at the 
trailing edge. Several molecules and pathways are known to be involved in these processes that 
conclude the “migration cycle” and prepare the cell for the next cycle, including FAK-Src 
complex recruitment and activity towards FA disassembly [142], ERK-mediated activation of 
calpain protease capable of severing actin, integrin, vinculin and talin molecules at FAs [143], 
and the cofilin pathway responsible for severing and elongation of actin filaments, thereby 
serving a main regulator for invasive directionality [144]. 
 
2.1.3.3. Migration patterns and strategies 
 Important for migration and invasion is the observation that tumor cells can acquire 
different migration patterns (collective vs. single-cell migration) as well as different strategies 
for migration that are used for each of these patterns [125, 145]. This may have significant 
implications when attempting to target migration/invasion of cancer cells of various types. The 
most well-known migratory pattern is the single-cell migration which occurs in the majority of 
solid stromal tumors, lymphomas, leukemias and generally, in all poorly-differentiated tumors 
[146]. Single-migratory tumor cells have been shown to use two main strategies for their 
motility; mesenchymal and amoeboid. In mesenchymal migration tumor cells undergo through 
the “migratory cycle” after changing morphology by the classic EMT, as described above. 
23 
 
Briefly, this is facilitated by cell elongation and loss of cellular polarity through down-regulation 
of E-cadherin, cytokeratins, catenins and other important adhesion molecules, and through 
secretion of matrix metalloproteinases (MMPs) that degrade the ECM [145]. As mentioned, this 
type of migration is largely controlled by formation of cell protrusions and FAs and actomyosin 
contraction of cytoplasmic stress fibers. 
In contrast, tumor cells may also show amoeboid migration which is characterized by 
spherical-shaped cells that invade vessels through pre-existing gaps in the ECM. This form of 
migration was determined an escape mechanism of mesenchymal-like tumor cells after inhibition 
of their associated matrix proteases; the transition between these migration strategies was termed 
mesenchymal-amoeboid transition (MAT) [147]. Amoeboid migration was found to be much 
less dependent upon integrin-ECM binding, maturation of focal adhesions or presence of 
cytoplasmic stress fibers [145]. Studies of the amoeboid cell structure were performed mainly on 
leukocytes; these revealed that cortical-actin filament polymerization controlled by RhoA/ROCK 
activity endow the cells the stiffness, tension, and contraction needed to push collagen matrix 
away for migration [148, 149]. Obviously, tumor cells that are able to switch between 
mesenchymal and amoeboid modes of motility would be resistant to agents aimed at either one 
of these strategies. Rather, it was suggested that a combination of protease inhibitors and ROCK 
inhibitors might act synergistically to better prevent tumor cell invasion [150]. 
A different migration pattern to single-cell migration is collective cell migration which 
has been commonly described to occur in epithelial tumors showing absence of EMT and 
preservation of cadherin-mediated cell-cell adhesion. This type of migration seems to 
predominate in highly- or intermediately-differentiated epithelial tumors; Strands/sheets of tumor 
cells have been detected as the main route of local invasion in epithelial tumors such as ductal 
24 
 
breast carcinoma [151], squamous cell carcinoma [152], and colon carcinoma [153], but also in 
mesenchymal rhabdomyosarcoma [151]. It is suspected that this form of migration is selectively 
advantageous as the heterogeneous cluster of cells maintains a wider variety of capabilities 
necessary for completion of the metastatic cascade [125]. 
 
2.1.3.4. Intravasation, transport and extravasation 
 Once tumor cells have gained the ability to migrate from the bulk of the primary 
tumor and invade the ECM they must intravasate into blood and/or lymph vessels in their 
journey toward the site of secondary metastasis. The local microenvironment seems to play a 
crucial role in this process as invading tumor cells seem to recruit tumor associated macrophages 
(TAM’s) to guide them to the location of blood vessels where intravasation will occur [154]. The 
interaction between tumor cells and TAM’s has been described to be dependent upon a paracrine 
signaling loop where colony stimulating factor-1 (CSF-1) receptor is expressed on TAM’s and 
epidermal growth factor receptor (EGFR) is expressed on tumor cells, and chemotaxis migration 
of both cells is toward a gradient of CSF-1 and EGF [155]. Another factor that seems to be of 
help for tumor cells to accomplish intravasation is the defective architecture and “leakiness” the 
tumor-associated vasculature. Maybe even easier to traverse are the walls of lymphatic vessels as 
these lack tight intercellular junctions between their endothelial cells [156]. A large variety of 
adhesion molecules then serve for attachment of tumor cells to endothelium at the primary tumor 
site, including but not only VLA-4 (α4β1 integrin), E-selectin and VCAM-1 [157], which then 
leads to their entrance into the blood/lymphatic circulation. 
Following intravasation, tumor cells are transported in the circulation system. In fact, it 
has been well documented that thousands to millions of tumor cells are shed from primary 
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tumors every day [7, 8]. Still, a very small proportion of these are fully metastatic as, generally, 
only a small number of metastatic nodules form at secondary sites in various models of 
metastasis. A few impeding factors that have been linked with this phase of transport in the 
circulation have been offered to explain this disparity. First, some of the cells that intravasate are 
destroyed by fragmentation as soon as they enter the blood stream due to the shearing forces 
mediated by the pressure of blood flow, an event that renders these cells to be non-metastatic in 
their potential [158]. In this regard, it appears that mesenchymal to spheroid (amoeboid) 
transition is important during this stage as amoeboid tumor cells survive better in this 
environment of high pressures [158]. Secondly, tumor cells are subjected to constant surveillance 
and killing by cells of the immune system [158, 159]. Despite these factors, it has been 
documented that a relatively high proportion of tumor cells are still able to extravasate into 
secondary organs [5, 6], leading to the notion that although a critical step in the metastatic 
cascade, intravasation and transport in circulation are probably not rate-limiting steps for this 
process. 
Tumor cell extravasation is generally thought to involve similar mechanisms to those that 
occur during intravasation. Namely, tumor cells use integrin and selectin molecules to interact 
with platelets, leukocytes and endothelial cells at the distant site to facilitate their arrest and 
invasion. Homing of tumor cells to specific organs also has importance in dictating the location 
of cell extravasation. Vascular endothelial growth factor 1 (VEGF-1) has a pivotal role in this 
stage of metastasis, providing not only the growth signals for disseminated tumor cells but also 
influencing on the tropism of certain tumor cells to distant sites [160]. The stromal-derived 
factor-1 (SDF-1)-CXCR4-CXCL12 chemokine axis is another signal that was found important 
for homing of tumor cells [161]. All together, these pathways (along with many other pathways 
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not mentioned here) conclude with the dissemination of tumor cells into sites where they may 
proceed to become fully-grown metastases. 
 
2.1.3.5. Outgrowth of disseminated tumor cells: Metastatic inefficiency mediated by anoikis 
 The outgrowth of disseminated tumor cells at secondary sites is dependent upon a 
complex interaction between the tumor cells and the target organ. Correlating with the “seed and 
soil hypothesis”, all of the conditions mentioned above have to be met for a successful 
implantation of tumor cells at the distant site. However, further positive interaction would have 
to occur between the tumor cell and the “new” microenvironment for the cells to proliferate and 
outgrow secondary tumors; without this, these cells, being “foreign” to the new environment, 
would face anoikis. 
Anoikis (Greek for homelessness) is a form of programmed cell death that occurs after 
loss or inappropriate cell-ECM anchorage; this was first described in Madin-Darby Canine 
Kidney (MDCK) epithelial cells by Frisch et al. [162]. This specific form of apoptosis occurs 
normally in various stages of tissue growth and remodeling and is important for tissue 
homeostasis [163-165] but its implications on tumor progression and metastasis are of utmost 
interest [166-168]. This is especially important since anoikis can affect tumor cell death at any 
time during the metastatic cascade, starting after detachment from the primary tumor, then 
during migration/invasion, when traveling in the circulation and post-extravasation after reaching 
at the distant site [100]. It is clear then why anoikis resistance can play such a dramatic role in 
cancer progression and why re-establishment of anoikis responsiveness may have a significant 
impact on tumor metastasis [100, 169-171]. 
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Among some of the mechanisms found to be involved in anoikis there are two main cell 
adhesion mechanisms, one is regulated by cell anchorage to ECM and the other one by cell-cell 
adhesion. Both of these interactions mediate downstream signaling pathways that are crucial for 
cell survival and proliferation and for suppression of apoptosis. Without these signals there 
becomes a stimuli for the initiation of apoptotic pathways, inducing either the death receptor 
pathway with upregulation of Fas ligand/Fas receptor and Fas-Associated Death Domain 
(FADD)-dependent caspase 8 activation and/or induction of the mitochondrial pathway for 
caspase activation due to ECM detachment-dependent translocation of Bax to mitochondria and 
cytochrome C-mediated apoptosis (reviewed in [167]). 
Cell-matrix anchorage is made primarily by integrin attachment to extracellular elements 
including fibronectin, laminin, fibrinogen and others [172]. Integrins are α/β transmembrane 
heterodimers that serve as scaffolds for adaptors and signaling intermediates. Various α/β subunit 
combinations have been found to be involved in different signal transduction pathways 
summarized in Figure 2.8. Important for anoikis, integrin activity allows the recruitment of two 
key-player kinases, FAK and ILK, both of which have a central role in anoikis resistance. Once 
FAK is ligated to integrin, it becomes auto-phosphorylated, a critical event for suppression of 
anoikis and sufficient for cell transformation [173]. FAK phosphorylation allows the recruitment 
and phosphorylation of other signaling elements and downstream signaling through 
phosphatidylinositol-3 kinase (PI-3K) and PKB/Akt [174], MAPK/ERK pathway [175], and JNK 
pathway [176]. ILK interacts specifically with β1, β2, and β3 subunits of integrin and activates 
PKB/Akt kinase activity [177]. Various studies have proven the fundamental function of ILK 
and FAK in anoikis regulation by showing that their overexpression suppresses anoikis after loss 
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of cell anchorage [173, 178-181]. Concordantly, dominant negative proteins and RNA silencing 
for ILK or PKB induce programmed cell death despite appropriate anchorage [177, 180, 182]. 
Cell-cell adhesion with its associated downstream signaling is maintained mostly through 
homotypic or heterotypic binding of various subtype cadherins. Cadherins are calcium-
dependent glycoproteins that produce tight connections between adjacent cells via catenin 
molecules that are attached themselves to the actin cytoskeleton of the cell [183]. Many studies 
provide evidence for the importance of cadherin signaling in regulation of anoikis vs. cell 
survival. For example, E-cadherin plays a role in the induction of apoptosis after loss of cell-cell 
anchorage in normal enterocytes [184] and colonic epithelial cells [185]. A similar effect was 
achieved through the blocking of E-cadherin with specific antibodies, whereas the induction of 
E-cadherin activity increased anoikis resistance [184]. Similarly, a study performed in human 
breast cancer cells also found that E-cadherin signaling is imperative for anoikis resistance and 
that blockade of E-cadherin induced cellular apoptosis [186]. Moreover, manipulations on the 
activity of E-cadherin that yielded anoikis resistance also supported a more metastatic phenotype 
in these cells with the induction of EMT and increased invasiveness [186]. E-cadherin maintains 
cell-cell anchorage-mediated survival through several known pathways, but most importantly, 
through PKB/Akt activity. In MDCK cells, E-cadherin activation through cell-cell adhesion 
mediated phosphorylation of PI3K and subsequent activation of Akt [187]. 
As it can be noticed, PKB/Akt activity makes a convergence point for both cell-matrix 
and cell-cell anchorage signaling and has a central role in cell survival. PKB/Akt is a serine-
threonine kinase that affects some of the most important mediators in the apoptotic machinery 
[188]. For example, Akt kinase phosphorylates and inactivates caspase 9, one of the prominent 
caspases in the intrinsic apoptotic pathway [189]. Akt also phosphorylates the Bcl-2 family 
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member, Bad, and consequently suppresses intrinsic-mediated apoptosis and promotes cell 
survival [190]. It was also found that Akt blocks the transcription of death-associated genes such 
as Fas ligand by phosphorylation and inactivation of FKHRL1, a transcription factor from the 
Forkhead family [191], and that Akt can activate NF-kB through activation of IkB kinase (IKK) 
to maintain survival signals [192]. As it can be expected, the inactivity of PKB/Akt prevents all 
of the above survival signals and releases mediators to promote their cell-death inducing 
pathways including a change in balance between Bad/Bcl-2, activity of caspase 9, Fas 
ligand/receptor expression and reduced NF-kB signaling [188]. 
 
2.1.3.6. Metastasis is an inefficient biological process 
 Evidence from multiple studies show that despite daily shedding of millions of tumor 
cells from a primary tumor site, the formation of metastases occurs at a relatively low frequency 
[5, 7, 9-11, 90]. In-depth research of the events taking place during metastasis has led to the 
realization that some of the steps in the cascade are very inefficient while some are very potent in 
nature. Specifically, the steps that occur early in the cascade, including invasion/migration, 
intravasation and extravasation are known to be highly efficient and not rate limiting for 
metastasis. This postulation is supported by the high numbers of tumor cells that successfully 
arrive and arrest within secondary organs after detachment from the primary site [5, 6, 11, 158]. 
In contrast, the stages during which tumor cells travel in systemic circulation and the 
events that take place post-extravasation have been documented as being highly inefficient. 
During their passage in the circulation, metastatic tumor cells have to withstand the impact of 
many microenvironmental factors such as the loss of cell-anchorage leading to cell death, killing 
by the constant surveillance of the immune system, and destruction by the sheer forces of blood 
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flow in the vasculature [44, 87-89]. Indeed, it has been shown that a large proportion of 
circulating tumor cells is destroyed upon entrance to blood vessels or during their travel in 
systemic circulation [9, 158, 193]. Specific evidence for post-extravasation inefficiency comes 
from various experimental tumor models and imaging techniques, including high resolution in 
vivo video-microscopy studies and quantitative cell-fate analysis after injection of tumor cells 
into mice. These show that a large proportion of the cells able to survive the early steps of 
extravasation and arrival at the future metastatic site, are unable to persist and establish their 
colonies, with only a small number of cells able to form micrometastatic lesions [5, 6, 9-11, 
158]. This may suggest that the most rate-limiting steps in metastasis occur after extravasation 
and that these limit or dictate the absolute success of metastases development. Most likely, one 
of the major events that results in death of large fractions of tumor cells once at the gates of the 
target organ is anoikis. As such, investigational anti-metastatic therapies which perturb these 
highly inefficient steps, specifically, treatments that can inhibit anoikis resistance and prevent 
cell migration and invasion post extravasation, would most likely exert the greatest therapeutic 
benefit. 
 
2.2. Rho GTPases 
2.2.1. Overview 
 Rho GTPases are molecular switch proteins that are involved in the regulation of a 
large variety of signaling pathways in the mammalian cell. These proteins switch between an 
active GTP-bound state and inactive GDP-bound state, which controls their ability to activate 
their effector molecules. There are currently hundreds of GTPases recognized in mammalian 
cells, and Rho GTPases are grouped under the Ras superfamily that contains over 60 GTPases. 
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There are 20 different Rho GTPases that were identified thus far but the best characterized 
members of the family are Rho, Rac and Cdc42 [12]. These proteins have been found as key 
regulators in one of the most important determinants for tumor cell migration and invasion; that 
is actin cytoskeleton rearrangement [194]. In this regard, Rho GTPases are important for cell 
morphology, movement and behavior. Rho GTPases have also been shown to be crucial for 
many aspects of tumorigenesis including tumor cell adhesion and migration [123, 134], 
stimulation of tumor cell invasion [195], angiogenesis [196] and anoikis [197, 198]. Other than 
that, they take part in control of other functions linked to actin cytoskeleton including gene 
transcription, G1 cell cycle progression, microtubule dynamics, vesicle transport and a wide 
variety of enzymatic activities [12]. Thus, these proteins make a viable and important target for 
cancer therapy. 
 
2.2.2. Function, regulation and signaling 
 Rho GTPases function as regulators of many signaling pathways, a function of which 
they can execute only after certain conditions have been successfully met. First, all Rho 
GTPases must undergo prenylation at their C-terminus end; this facilitates proper localization 
and anchorage to the inner layer of the cell membrane and helps in protein-protein interactions 
[17]. Once at the level of the cell membrane Rho GTPases become activated by guanine 
nucleotide exchange factors (GEFs), of which there are approximately 60 known proteins that 
are able to switch GDP for GTP (Figure 2.9) [13]. Rho GEFs mainly include the Dbl-family 
proteins which have specific interactions with Rho GTPases via Dbl homology (DH) and 
pleckstrin homology (PH) domains [199]. GEFs act downstream to important signaling 
mediators including growth factor receptors, integrins, cadherins and cytokine receptors and 
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hence serve as signaling nodes for coordinated temporal and spatial activation of Rho GTPases 
[13]. Following activation, the Rho GTPase then interacts with one of 60 known effector 
molecules which stimulate various downstream signaling cascades for organization of actin 
cytoskeleton, cell cycle progression and gene expression [12, 199]. Not all mechanisms by 
which GTP-bound Rho GTPases activate their effector molecules have been clarified but where 
evidence exists it appears that their presence at the level of inner portion of the cytoplasmic 
membrane allows a conformational change of the effector from an inactive to active state. In the 
case of ROCK, a pleckstrin homology region at the C-terminus of the protein is normally folded 
over the kinase domain and serves as an autoinhibitory loop; binding with RhoA-GTP disrupts 
this negative interaction and allows kinase activity [200, 201]. As another example, activation of 
p21-activated kinase 1 (PAK1), an effector of both Cdc42 and Rac1, was shown to occur by 
induction of a conformational change in the kinase inhibitory domain (KID) of the protein after 
binding with Cdc42-GTP; this removes the dis-inhibition of the catalytic domain and results in 
autophosphorylation and activation of PAK1 [202]. 
Inactivation of Rho GTPases can occur at two levels; GTP hydrolysis or stabilization in a 
GDP-bound form. GTP hydrolysis is facilitated by the action of GTPase-activating proteins 
(GAPs), a family of more than 70 proteins. Sequestration of inactive Rho-GDP proteins from the 
plasma membrane leads to their stabilization in this inactivated form, a process that occurs by 
complexing with Rho guanine nucleotide dissociation inhibitors (RhoGDIs) [203]. Interestingly, 
and although functional only at the level of the cell membrane, approximately 90-95% of Rho 
GTPases are found in the cytosol bound to RhoGDIs. An acceptable explanation for this finding 
is that this allows for rapid cellular response to specific signals with translocation and activation 
of any particular Rho GTPase when necessary [203]. RhoGDIs are important not only for 
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keeping a large reservoir of Rho GTPases but also for protecting them from degradation by the 
proteasome; The prenyl group attached to Rho GTPases prevents them from folding properly 
and makes them unstable and prone to degradation and RhoGDIs protect this hydrophobic group 
and act as chaperones to stabilize mature Rho GTPases prior to their anchorage to the membrane 
(Figure 2.10) [204]. 
 
2.2.3 The mevalonate pathway and prenylation of Rho GTPases 
 As previously mentioned, Rho GTPase activation and interaction with downstream 
effector proteins depends upon their anchorage to the inner leaflet of the plasma membrane. In 
order for this to occur, Rho GTPases must undergo a post-translational modification called 
isoprenylation. Protein prenylation is a process in which pyrophosphate molecules, the products 
of the mevalonate pathway (Figure 2.11), are added by enzymatic activity at the CaaX or CxC 
motif located at the C-terminus of target proteins; this process is not unique for Rho GTPases 
and can occur in other proteins that require this modification for attachment to the cell membrane 
[17]. There are three different enzymes known to catalyze this activity; namely farnesyl 
transferase (FTase), geranylgeranyl transferase type I (GGTase-I) and geranylgeranyl transferase 
type II (GGTase-II) [205]. However, it appears that there is specificity for enzyme activity on the 
various targets; GGTase-I was found as the preferential prenylating enzyme for the canonical 
Rho GTPases, RhoA, RhoC, Rac1, and Cdc42, adding geranylgeranyl pyrophosphate (GGPP) to 
the 4
th
 to last cysteine residue at the C-terminus after removing the aaX tripeptide motif [206]. 
Figure 2.12 summarizes the steps that take place during protein prenylation. 
 
2.2.4 Involvement in tumorigenesis and targeting for cancer treatment 
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 There is a large body of evidence to point at Rho GTPases as regulators of a wide array 
of cellular processes that are specifically linked to tumorigenesis and tumor cell metastasis 
(reviewed in [207]). The most prevalent mechanism implicated for Rho GTPases in human 
malignancies is by overexpression of their gene levels. Figure 2.13 shows tumor relevant 
functions of Rho GTPases and follows is detailed information on their role in tumor cell 
migration/invasion, anoikis resistance, and metastasis and on the targeting of Rho GTPases for 
cancer treatment. 
 
2.2.4.1 Rho GTPases and cell motility 
 RhoA, RhoC, Rac1, and Cdc42 are the best documented proteins of the group in what 
relates to regulation of the actin cytoskeleton, and their activity has been shown to coordinate 
directional motion of cells, specifically cancer cells ([208] and reviewed in [194, 209, 210]). 
Each one of these proteins has specific roles in cytoskeletal rearrangement and they control the 
production of different cellular protrusions and contracting elements that play a role in the 
“migration cycle” (see 2.1.3.2). 
RhoA and RhoC are active mainly at the rear end of migrating cells, promoting cell 
detachment by contraction of actin stress fibers and loosening of focal adhesions [14]. RhoA 
stimulates the formation of stress fibers through polymerization of actin monomers to the barbed 
end of actin filaments; this activity is promoted by activation of mDia proteins and Rho-kinases 
(ROCK I and ROCK II), both of which are direct effectors of RhoA and RhoC (Figure 2.14) 
[14]. ROCK activity is also important for the contractility of actomyosin fibers as it 
phosphorylates and inactivates myosin phosphatase [211] and phosphorylates myosin light chain 
(MLC) [15, 16]. 
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ROCK and Dia1 have been shown to also affect the stability of cell-cell adherence 
junctions which plays a role in determining the migratory ability of adherent cells; ROCK 
activity and actomyosin contraction resulted in disruption of adherence junctions and this was 
more related to activity downstream to RhoC than RhoA [212]. Correlating with this, ROCK also 
appears to regulate “mesenchymal migration” of tumor cells typified by cell elongation and loss 
of cellular polarity through down-regulation of adhesion molecules, formation of cell 
protrusions, stress fibers, and FAs for contraction, and through secretion of MMPs [212]. In this 
regard, RhoA and Cdc42 activity was shown necessary for the localization and secretion of 
MMPs at sites of invadopodia formation [109] and ROCK was suggested to be involved in 
MMPs activation and exocytosis from invadopodia as its inhibition decreased their activity and 
decreased cancer cell invasion [213]. 
ECM-cell adhesion through integrin binding is also regulated by Rho proteins and it is 
hypothesized that this occurs by modulation of integrin avidity by Rho and increased rate of 
clustering at FAs. These, in turn, are thought to initiate post-ligand binding events that control 
the strength of cell adhesion and the quality and quantity of signaling events downstream of 
integrins [138]. 
Cdc42 and Rac1 are mainly active at the leading edge of the cell where they control 
polarization towards the direction of movement, extension of cell protrusions, and cell-matrix 
interaction at focal complexes [14, 208, 209]. After activation, both proteins activate their own 
set of effectors; however there is some redundancy in their activity and also feedback control that 
occurs between these regulators [214]. Cdc42 is a main regulator of cell polarization and it 
controls the formation of the highly dynamic finger-like actin-rich protrusions termed filopodia 
(Figure 2.15). These are made of parallel bundles of F-actin and serve as sensors of the 
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environment during formation of cell-cell contacts [214]. The three main effector proteins of 
Cdc42 include p21-activated kinase (PAK), mDia2 and actin-related protein-2/3 (ARP2/3); the 
coordinated activity of these proteins leads to continuous actin polymerization for extension of 
filopodia and turnover of actin monomers at the negative end of filaments [134, 214]. The 
chemoattractant gradient that determines cell polarization can be very small but it is amplified by 
the reciprocal activity of PI3K and PTEN which translates into an intracellular gradient of PIP3 
molecules [215]; PIP3 levels determine the location of Cdc42 activity and translate the 
chemoattractant gradient to polarized migration [216]. 
Rac1 controls the production and extension of lamellipodia structures and the formation 
of new focal adhesion complexes that attach the ECM as the cell migrates forward [208, 209]. 
Similar to Cdc42, Rac1 also activates PAK, mDia2 and ARP2/3 (Figure 2.15) but their activity 
here allows for production of a branching actin network making the sheet-like structure typical of 
lamellipodia. The activity of Rac1 also needs to be localized to the leading edge and, similar to 
Cdc42, this is also thought to occur by PI3K activity and the localization pattern of its PIP3 
products [128]. Rac1 also operates to make focal complex assembly which serve as points of 
traction for the cell along its movement; the interaction of the lamellipodia with ECM signals for 
integrin clustering together with FAK, α-actinin, talin, vinculin, paxillin, and other regulatory 
proteins, all of which make a focal complex adhesion unit [217]. Several feedback loops further 
drive Rac GTP activation, including Rac stimulation by integrin clusters made in the newly 
formed focal adhesion and Rac self-activation of PI3K which produces PIP3 molecules able to 
activate PIP3-sensitive Rac-GEFs [218]. 
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2.2.4.2 Rho GTPases are a viable drug target due to their contribution to anoikis resistance 
and metastatic cell phenotype 
 Given the above data, it is not surprising that Rho GTPases and their effector 
molecules have been found to be directly linked to tumorigenesis and metastasis, lending them to 
be important targets for cancer therapy [18, 19]. Their contribution to metastasis is exemplified 
in many levels. For instance, increased ROCK activity is linked with increased invasiveness of 
cancer cells in various models. ROCK was linked with increased invasiveness in rat hepatoma 
cells and inhibition of ROCK activity with a specific ROCK inhibitor (Y-27632) or with a 
dominant negative kinase-defective ROCK mutant has blocked this effect [219]. Similar invasive 
effects were found in constantly active RhoA-transfected hepatoma cells and these were blocked 
with the use of the specific RhoA/RhoC inhibitor, Botulinum exoenzyme C3 [195]. Rho-ROCK 
activity was also reported to induce polarization and migration of Walker 256 carcinosarcoma 
cells [220], drive invasion and protrusion of sarcoma cells [221] and migration of small cell lung 
cancer cells [222]. Inhibition of ROCK in mouse models prevented metastasis of human breast 
cancer cells to human bone [20] and intrahepatic spread of human hepatocellular carcinoma cells 
[21]. 
Both Rac1 and Cdc42 were also shown to be involved in progression of cancer in vitro 
and in vivo. For example, both proteins were found to be overexpressed in human breast cancer 
tissue [223] and in tissues from human testicular cancer [224]. Rac1 overexpression was also 
found to correlate with progression of human gastric carcinoma [225] and oral SCC neoplasia 
[226]. Interestingly, Rac1, as well as Cdc42 and RhoA, are directly activated by the p210 BCR-
ABL oncoprotein that operates as a GEF, and chronic myelogenous leukemia (CML) of both 
mice and humans is linked with increased activity of Rac [227]. 
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As previously mentioned (in 2.1.3.5), anoikis resistance by tumor cells has an important 
role in evasion from normal growth control mechanisms by giving a survival advantage for 
migrating cancer cells over normally regulated detaching cells and Rho GTPases have been 
found to be involved in this process. Two main kinases implicated as regulators of anoikis and 
anoikis resistance are PI3K and PKB/Akt, but other various proteins are involved in this 
signaling cascade such as integrin signaling through ILK (Integrin-like kinase) and FAK, and E-
cadherin intracellular signaling pathways [165]. Cheng et al. found that Rho GTPases are 
involved in conferring anoikis resistance by their ability to activate PI3K and PKB/Akt [197]. In 
this study, GTP-bound Cdc42 and Rac1 were found to bind directly to the p85 regulatory subunit 
of PI3K and activate it in MDCK cells, resulting in activation of PKB and anoikis resistance 
[197]. In these cells, disruption of the actin cytoskeleton with Latrunculin B (inhibitor of actin 
polymerization) inhibited the protective effects conferred by Cdc42 and Rac1 but did not prevent 
PI3K-mediated anoikis. This suggested that Cdc42 and Rac1 regulate anoikis resistance by two 
different mechanisms: 1. Activation of PI3K/Akt (independent of intact cytoskeleton). 2. 
Regulation of actin cytoskeleton reorganization by Cdc42 and Rac1 [197]. In another study using 
MDCK cells it was similarly found that Rac1 contributes to anoikis resistance specifically 
through PI3K activation and downstream signaling [228]. Lastly, Cdc42 double negative 
NIH3T3 cells showed deficient colony formation ability, a trait related to inhibited anchorage-
independent growth, and the addition of a constitutively active Cdc42 to these cells rescued this 
phenotype [166]. 
There are a few lines of evidence that Rho/ROCK activity also regulates anoikis. For 
example, RhoA-ROCK I signaling was found to regulate the growth of invasive lobular breast 
carcinoma cells in the absence of cell anchorage [229]. In this study it was found that loss of E-
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cadherin signaling leads to cytosolic translocation of p120-catenin, which after interaction with 
myosin phosphatase Rho–interacting protein (Mrip), allowed activation of RhoA-ROCK I 
pathway and anchorage-independent growth [229]. Furthermore, ROCK inhibition by Y-27632 
resulted in inhibition of anchorage-independent growth in colorectal tumor cell lines [198]. 
The involvement of Rho GTPases in so many levels of cancer progression and metastasis 
led to active research attempting to find effective drugs to target these proteins and achieve anti-
cancer effects. So far, two main families of drugs were found to target the prenylation of Rho 
GTPases by inhibition of enzymes in the mevalonate pathway; the statins and the 
bisphosphonates [18]. Statins inhibit the HMG-CoA reductase enzyme of the mevalonate 
pathway; a crucial enzyme for the production of cholesterol (Figure 2.16). The inhibition of 
Acetyl CoA metabolism prevents production of other sterol, dolichol, squalene and cholesterol, 
as well as prenyl molecules [230]. The use of various statins resulted in reduction in tumor cell 
invasion, metastasis and growth in different tumor types and tumor models [231-234]. 
Specifically, targeting of RhoA/ROCK activity was proven to occur in various tumor types and 
this has inhibited their growth and invasiveness [22, 23, 235, 236]. Bisphosphonate drugs are 
also implicated in targeting and inhibiting protein prenylation by specific inhibition of an 
enzyme of the mevalonate pathway, farnesyl pyrophosphate synthase (FPP synthase), thereby 
inhibiting the production of farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate 
(GGPP) (Figure 2.16) [237]. The potential of these drugs is well established for inhibition of 
bone resorption by induction of osteoclast apoptosis [238, 239] and this was proven as being 
therapeutic in humans for both osteoporosis [240] and malignant osteolysis [241]. These results 
are not surprising given that bisphosphonates concentrate and bind to bone ECM, especially to 
sites of high bone turnover [237]. Other than these properties, bisphosphonates also appear to 
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have direct anti-tumor effects by inhibition of tumor cell adhesion, migration, invasion, survival 
and proliferation in vitro [242, 243]. Treatment with several of the bisphosphonate drugs resulted 
in delay and inhibition of bone metastases in animal models of carcinomas and sarcomas but 
there is conflicting data and uncertainty in the ability of these agents to inhibit visceral tumor 
spread [243]; further research is necessary to define the impact of bisphosphonates on visceral 
metastasis and the mechanisms by which this may occur. 
 
2.3 Zoledronate: anti-cancer activity 
2.3.1 Current use, structure, and activity 
 Zoledronate (zoledronic acid, ZOL) is a nitrogen-containing bisphosphonate (N-BP) 
that has raised interest in the oncologic community over the past decade after it was approved by 
the FDA in 2002 for the treatment of skeletal complications related to tumor-mediated osteolysis 
of solid tumors (prostate, breast and lung carcinoma) and multiple myeloma. Since then, 
extensive research has been made in attempt to define the anti-cancer capabilities of this drug 
and to analyze the mechanisms by which these occur. Currently, ZOL shows efficacy in 
treatment of human patients with cancer of the breast, prostate, lung, and kidney as well as in 
patients with other solid tumors and multiple myeloma, inducing significant reductions in bone 
turnover markers, bone pain, and skeletal-related events (SRE) compared to placebo-treated 
patients [25, 26]. 
ZOL is a synthetic, non-hydrolysable, analogue of pyrophosphate (PPi, P-O-P) in which 
the oxygen atom has been replaced by a carbon atom (P-C-P) and two side chains (R1, R2) were 
covalently added (Figure 2.17). R1 side chain is made of a hydroxyl group which allows for the 
strong bonding of the molecule to Ca
2+
 ions; this property allows for fast clearance of the drug 
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from the circulation and selective binding to bone matrix, especially at sites of osteoclast activity 
and high bone turnover [237]. R2 side chain contains a heterocyclic nitrogen-containing ring that 
confers the anti-resorptive capacity of this drug [237]. 
Studies of the molecule have shown that the structure of R2 side chain is the most 
important feature that allows the inhibition of FPP synthase enzyme of the mevalonate pathway 
[244, 245]. Of all N-BPs, ZOL has the lowest dissociation constant (Ki) which is due to the 
“slow tight bonding” it makes at the substrate pocket of FPP synthase [237], and it was found 
that it can inhibit this enzyme at even just picomolar concentrations [245]. Since FPP synthase is 
highly conserved and abundantly present in all cell types, the sensitivity of cells to ZOL depends 
mostly on their ability to internalize the drug; the high selectivity towards osteoclasts can be 
explained by the affinity of ZOL to sites of active bone remodeling where osteoclasts are highly 
concentrated and calcium is abundant [244]. 
 
2.3.2 ZOL anti-tumor mechanisms of action 
 In vitro use of ZOL in tumor and non-tumor cells produced many lines of evidence that 
it can be of benefit for treatment of cancer. First, ZOL has the capability to inhibit adhesion to 
bone matrix which was shown to occur in prostate cancer cells [246]. This effect was found 
prenylation-dependent, and specifically related to geranylgeranylation and not farensylation, as it 
was reversed by supplementation of geranylgeraniol (GGOH) and much less so by 
supplementation of farnesol (FOH). Similar effects were produced with the use of GGTI-298, a 
specific inhibitor of GGTase I, and with C3 exoenzyme, a RhoA/RhoC inhibitor, leading to the 
conclusion that adhesion inhibition in these cells is related to Rho GTPase deregulation caused 
by blocking of prenylation [246]. 
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Secondly, and consistent with an anti-metastatic potential, ZOL was also shown to reduce 
tumor cell migration and invasion in various cell lines including breast, prostate and 
osteosarcoma cell lines [247-249]. Many mechanisms were described to be contributing to these 
ZOL-induced effects including interference with protein prenylation by targeting 
geranylgeranylation [249], RhoA-defective prenylation and cytoskeleton disorganization, and 
reduction in expression of CXCR4, the receptor for stromal-derived factor 1 (SDF-1) necessary 
for bone chemotaxis [248]. Also, cell invasion was hypothesized to be inhibited by N-BPs by 
chelation of zinc ions and inhibition of MMP-2, -9, and -12 activity (although these occurred at 
relatively high drug concentrations of more than 100µM) [247]. In vivo, it was found that ZOL 
treatment caused reduced expression of MMP-2 and MMP-9 in PC-3 (prostate carcinoma cell 
line)-induced tibia osteolytic lesions [250]. 
Lastly, zoledronate may be affecting tumor cell growth by interfering with the pro-
tumorigenic microenvironment and tumor angiogenesis. Evidence for this is present with the 
blocking of human umbilical endothelial cells (HUVEC) from performing adhesion, and 
migration and inhibiting their survival following ZOL treatment; this coincided with disruption 
of focal adhesions and stress fiber formation [251]. These effects were postulated to be the result 
of targeting of the FAK-PKB/Akt pathway for cell survival, potentially impinging on cancer-
related angiogenesis [251]. In another study, similar inhibitory effects were found on HUVEC 
cell proliferation, adhesion and migration, and ZOL also inhibited angiogenesis towards a 
subcutaneous implant impregnated with bFGF [252]. Consistent with these findings is the report 
of significant decreases in levels of VEGF and PDGF in the blood circulation of cancer patients 
after a single injection of ZOL [253]. All of these effects were not directly linked with inhibition 
of Rho GTPase activity but several studies provide evidence for the pro-angiogenic effects of 
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Rho GTPases (reviewed by [196]). Specifically, RhoC was shown to act as the downstream 
regulator of VEGF and that it restrains angiogenesis of hepatocellular carcinoma cells by 
blocking reorganization of F-actin filaments necessary for endothelial cell network and sprout 
formation [254]. Similarly, Rac1 also appears to be regulated by VEGF, inducing production of 
lamellipodia and membrane ruffles by activating the Rac1-specific GEF, Vav2 [255]. Another 
mechanism that was hypothesized to affect the “angiogenic switch” was the inhibitory activity 
that ZOL might have on tumor associated macrophages (TAMs), reducing their secretion of pro-
invasion and pro-angiogenic factors, as well as reversing their phenotype from M2 (pro-tumor) 
to M1 (tumoricidal) [256]. This may have significant implications on the regulation of the tumor 
microenvironment and the pre-metastatic niche. 
 
2.3.3 In vivo tumor models and outcome with ZOL treatment 
 The vast majority of data from in vivo models supports an important role for ZOL in 
inhibition of malignant osteolysis, explaining it by mechanisms described above such as direct 
inhibition of osteoclast activity and proliferation, inhibition of tumor cell adhesion to bone 
matrix, blocking of tumor cell invasion and migration, and changes associated with the tumor 
microenvironment and angiogenesis [250, 257, 258]. In a mouse model of multiple myeloma 
using 5T2MM cells, treatment with ZOL prevented the formation of osteolytic bone lesions, 
decreased the tumor cell burden in the marrow cavity and reduced angiogenesis as shown with 
reduced microvessel density [257]. In another mouse model for bone metastasis of MDA-MB-
231 breast carcinoma cells to bones, treatment with ZOL resulted in significant decrease in the 
progression of established osteolytic lesions and in the expansion of tumor cells in bone [258]. 
The effects of ZOL treatment were also tested in a prostate carcinoma model, which is yet 
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another tumor with high propensity for bone metastasis [250]. Here, both tumor growth and bone 
degradation were inhibited by ZOL after intratibial injection of CaP cells, and this was 
hypothesized to be the result of direct effects of ZOL on tumor cells, indirect effects related to 
decreased bone lysis and decreased release of ECM-derived factors supportive of tumor cells 
growth, or a combination of both effects [250]. 
The findings of such significant effects of ZOL on a wide variety of events related to 
tumorigenesis and its impact on metastatic bone lesions had driven researchers to find whether 
ZOL may exert similar effects on processes related to extra-skeletal tumor spread (i.e. visceral 
metastasis). Unfortunately, the data from these studies is conflicting and difficult for 
interpretation. In an orthotopic mouse model of spontaneous bone, lung and liver metastasis of 
4T1/luc breast cancer, treatment with ZOL reduced both bone lesions and inhibited lung and 
liver metastasis with subsequent prolongation of survival time compared to untreated animals 
[28]. This was not accounted for by tumor cell apoptosis as there was increased numbers of 
apoptotic tumor cells only in the bone and not in the lung. The inhibition of visceral metastasis 
was accounted for by the inhibition of tumor cell migration and invasion visible in vitro [28]. 
Another study examined the effects of ZOL in an orthotopic model of osteosarcoma (OS) in 
mice and found similar results with not only reduction in primary tumor growth and reduced 
tumor-mediated osteolysis but also significant inhibition of lung metastasis [29]. Similar results 
were also found in 2 other studies using a heterotopic model of OS in mice [30, 31]. 
Conversely, other studies found no protective effect of ZOL treatment for the 
development of visceral metastasis. Single-agent ZOL used in nude mice after intra-tibial 
inoculation of OSCA40 (canine OS) cells resulted in reduced bone lysis but no significant 
reduction in lung metastases [259]. There were 2 other reports that investigated the effect of ZOL 
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in models of OS [260, 261]. In a rat orthotopic model ZOL was only able to reduce tumor-
mediated new bone formation at the site of cancer cell inoculation but there was otherwise no 
reduction in bone tumor burden and no protection from lung metastasis was found [261]. Very 
similar results were published by the same group in an orthotopic OS mouse model [260]. The 
differences between the results of these studies and the ones showing decreased lung metastasis 
are hard to explain but might be related to differences in cell lines/origin between models and 
also to differences in ZOL treatment regimen and doses that were used. 
 
2.3.4. Canine osteosarcoma and ZOL 
 Osteosarcoma (OS) is the most common primary bone tumor in dogs and accounts for 
nearly 10% of all diagnosed canine tumors [262, 263]. In dogs, the diagnosis of OSA is virtually 
a death sentence and despite 25 years of intensive efforts to improve the outcome with surgery, 
chemotherapy, and immunotherapy, the median survival time of dogs following diagnosis 
remains disappointingly static [264]. Canine OS shares nearly identical clinical behavior and 
genetic signatures as pediatric OS, and as such, dogs diagnosed with OS serve as a valuable 
comparative tumor model for the discovery and evaluation of novel therapeutics. 
Large and giant breed dogs are predisposed to developing OS, which principally arises 
from the metaphyseal regions of long bones [265]. Primary OS lesions grow in an expansile and 
destructive manner causing extensive pathologic osteolysis with extension into surrounding soft 
tissues [265-267]. In addition to the morbidity caused by painful focal malignant osteolysis, the 
mortality rate for OS in dogs exceeds 90% from the development of distant metastases involving 
most commonly the pulmonary parenchyma but also other visceral organs [266]. At present, the 
metastatic progression of canine OS remains relatively immutable despite aggressive 
46 
 
multimodality treatment strategies consisting of limb amputation and systemic chemotherapy 
[263-267]. Given the failure of traditional cancer therapies to markedly improve the outcome for 
dogs with OS, there is a compelling rationale to explore novel therapeutic approaches that may 
slow the progression or inhibit the development of distant metastases. 
Although preclinical studies demonstrate ZOL’s potential antimetastatic effect, a unifying 
molecular mechanism for these preclinical observations has yet to be reported. The use of ZOL 
has shown efficacy against visceral metastasis in OS models in a few studies [29-31], however 
others report no benefit for the use of ZOL in OS [259-261]. In this study we aimed to define the 
mechanisms by which ZOL may impact on the tumorigenic and metastatic capabilities of OS 
using in vitro and in vivo tumor models. We hypothesized that ZOL will impair Rho GTPase 
prenylation with subsequent perturbation of cytoskeletal rearrangement and motility in OS cells 
and that this will result in a decrease in the migratory capacity of tumor cells and lead to 
inhibition/reduction of lung metastasis. 
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CHAPTER 3 
MATERIALS AND METHODS 
 
3.1. Cells and reagents: 
 The mouse highly metastatic osteosarcoma cell line, K7M2, was developed in Dr. 
Khanna’s laboratory [268] and was generously gifted to our laboratory for this study. Cells were 
cultured at 37˚C in Dulbecco's Modified Eagle's Medium (DMEM) supplemented with glutamine 
(2 mmol/L), penicillin (100 IU/ml), streptomycin (100 IU/ml), and 10% fetal bovine serum 
(FBS) in a humidified atmosphere supplemented with 5% CO2. 
Zoledronate was generously provided by Novartis Pharma AG.  The GGTase I inhibitor 
GGTI-298 and Y-27632 ROCK inhibitor were purchased from Calbiochem. The cell permeable 
C3 transferase Rho inhibitor I (catalog # CT04) was purchased from Cytoskeleton, Inc. 
Geranylgeraniol (GGOH) was purchased from Sigma-Aldrich. Rho GTPase antibodies (RhoA 
mouse monoclonal; 26C4, RhoC goat polyclonal; K-12, Cdc42 mouse monoclonal; B-8) and 
MYL9 antibody (rabbit polyclonal; FL-172, catalog # sc-15370) were purchased from Santa 
Cruz Biotechnology Inc. Anti-Rac1 mouse monoclonal antibody (clone 23A8, catalog # 05-389) 
and anti-MLC2 phospho-specific (serine 19) polyclonal antibody (catalog # AB3381) were 
purchased from Millipore. Horseradish peroxidase conjugated anti-mouse and anti-goat 
secondary antibodies were purchased from GE Healthcare, UK. Anti-beta actin mouse 
monoclonal antibody (AC-15) was purchased from Abcam Biochemicals. Alexa Fluor 568 
phalloidin antibody (A12380), vinculin recombinant rabbit monoclonal antibody (700062), 
Alexa Fluor 488 goat anti-rabbit SFX kit (A31627) and ProLong Gold antifade reagent (catalog 
# P36934) were purchased from Invitrogen. 1μ-Slide 8 well chambers were purchased from Ibidi 
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(Germany, catalog # 80826) and were used for cell culture for immunofluorescence purposes as 
described below. 
 
3.2. Animals: 
 Female 8-10 week old balb/c mice (Charles River Laboratories, Wilmington, 
Massachusetts) were used for in vivo experimental metastasis assays as described below. Mice 
were housed in pathogen-free conditions and animal care and use was in accordance with the 
guidelines approved by the Illinois Institutional Animal Care and Use Committee (IACUC). 
 
3.3. Cell protein fractionation: 
 Cell protein was fractionated to cytoplasmic and membrane fractions for western analysis 
by procedure adapted from Zhong et al. [24]. Cells were grown in culture until determined end of 
experiment and then media was removed and cells were washed twice with ice-cold PBS. Cells 
were then scraped and centrifuged at 2,000 rpm at 4°C for 5 minutes. Supernatant was removed 
and the pellet was homogenized in a glass mortar and pestle after mixing pellet with lysis buffer 
containing 50 mM Hepes, 50 mM NaCl, 2mM EDTA, 1 mM MgCl2, 10 mM NaF, 1 mM DTT, 1 
mM PMSF and fresh Pierce protease inhibitor cocktail solution (diluted 1:100 for final working 
solution). Homogenate was transferred to ultracentrifuge eppendorfs and incubated on ice for 15 
minutes before centrifuging at 100,000 g for 30 minutes at 4°C. Supernatant was collected as the 
cytosolic fraction, and protein aliquots were stored at -80°C until further analysis. The residual 
pellet was homogenized in a glass mortar and pestle after mixing with lysis buffer containing 50 
mM Hepes, 50 mM NaCl, 2 mM EDTA, 1 mM MgCl2, 10 mM NaF, 1 mM DTT, 1 mM PMSF 
and fresh Pierce protease inhibitor cocktail solution (diluted 1:100 for final working solution) 
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and 2% Triton X-100. The homogenate was centrifuged at 10,000 rpm for 30 minutes at 4°C. 
The supernatant was collected as the membrane fraction and aliquots were stored at -80°C until 
further analysis. For all other protein samples extraction was done using a commercial reagent 
(M-PER, Pierce, Rockford, IL). 
 
3.4. Western blot analysis: 
 Cellular protein concentrations were determined using a standard assay kit (Bicinchoninic 
Acid Protein Assay, Rockford, IL). For each protein expression analysis, 50-80 µg samples were 
electrophoresed on 12% polyacrylamide gel and then electrophoretically transferred to 
nitrocellulose membrane. Western blot analysis was performed using Rho GTPase antibodies at 
various dilutions (RhoA 1:500, RhoC cytosolic fraction 1:500, RhoC membrane fraction 1:250, 
Rac1 1:500, Cdc42 1:250) in TBST with 1% milk. The membrane was then washed 3 times with 
TBST and probed with the secondary antibody diluted 1:1000 in TBST with 1% milk. Target 
proteins were detected by the enhanced chemiluminescence (ECL) detection system 
(Amersham). The ECL blots were developed using ChemiDoc XRS+ molecular imager system 
(Bio-Rad) with Image Lab software. Band volume analysis was done using Image J software 
(NIH) and results of each of the proteins were adjusted for β-actin expression levels used as a 
loading control or to the levels of the native protein (MYL9 for phospo-MLC2). Results reported 
were derived from at least 2 independent experiments. 
 
3.5. In vitro ZOL cytotoxicity analysis: 
 For analysis of cytotoxicity, an Annexin V-FITC PI apoptosis detection kit (BD 
Pharmingen, San Diego, California) was used according to the manufacturer’s directions. Cells 
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were incubated with their respective concentrations of ZOL for various durations of time and 
then media was collected separately from each culture and transferred to a flow cytometry tube. 
The analysis was done in triplicates using at least 1 x 10
5
 cells per tube. After collecting the 
media cells were trypsinized and collected to a flow cytometry tube using ice-cold PBS. Tubes 
were centrifuged at 2,000 rpm at 4°C for 5 minutes. The supernatant was removed and replaced 
with ice-cold PBS. Cells were gently re-suspended and centrifuged again as above. The 
supernatant was removed and cells were re-suspended in cold (4°C) binding buffer and stained 
using 5 µl of FITC Annexin V and 5 µl of PI. Cells were then gently mixed and incubated in the 
dark at room temperature for 15 minutes. Binding buffer (400µl) was then added to each of the 
samples and these were taken for analysis by flow cytometry using a BD Accuri C6 flow 
cytometer (BD Biosciences, USA). 
 
3.6. Confocal laser scanning immunofluorescence microscopy: 
 Cells were seeded at initial concentration of 2,000 cells per chamber and were grown in 
their respective ZOL concentrations for stated exposure durations in phenol red-free DMEM in 
1μ-Slide 8 well chambers (Ibidi, Germany). The cells were then washed twice with warm (37°C) 
phenol red-free DMEM free of FBS. For fast and optimal cell fixation, medium was removed 
and warm (37°C) phenol red-free DMEM free of FBS was added and then warm 8% methanol-
free paraformaldehyde (PFA) diluted in DMEM was added at 1:1 ratio to achieve a final 
concentration of 4% PFA. Fixation was done for 10 minutes at room temperature after which 
cells were washed 3 times with warm (37°C) PBS and then permeabilized for 5 minutes in room 
temperature using 0.1% Triton X-100 diluted in warm (37°C) PBS. Cells were then washed 3 
times with PBS and then pre-blocked with 5 drops of IT signal FX solution (SFX kit, Invitrogen) 
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for 30 minutes at room temperature. Cells were washed 3 times with PBS, blocked with 3% BSA 
in PBS for 30 minutes at room temperature and then washed again three times with PBS and 
incubated with anti-vinculin antibody (1:100 in 3% BSA in PBS) for 1 hour at room temperature. 
Cells were then washed 3 times with PBS and then incubated with secondary goat anti-rabbit 
Alexa fluor 488 antibody (1:200 in 3% BSA in PBS) for 90 minutes at room temperature while 
protected from light. Cells were then washed 3 times with PBS and incubated with phalloidin 
antibody prepared according to manufacturer’s instructions diluted in 3% BSA for 30 minutes at 
room temperature while being protected from light. Cells were then briefly washed once with 
PBS and mounted with 5 drops of ProLong Gold solution after which chambers were left to dry 
at room temperature for 24 hours while being protected from light and then kept in the dark at 
4°C until imaging. Immunofluorescence imaging was done using LSM 700 confocal laser 
scanning microscope (Zeiss; Thornwood, NY) and image analysis was done using Image J 
software (NIH). For analysis of staining at focal adhesion sites, fluorescence of both vinculin and 
phalloidin staining was measured at the cell periphery and compared between treated and 
untreated cells. The assay was repeated twice and measurements are reported as median 
fluorescence levels (pixels). 
 
3.7. In vitro migration assays: 
 Qualitative analysis of cell migration was done using the “scratch assay” method [269]. 
Briefly, cells were grown in culture in 6 well plates until reaching sub-confluence. A scratch was 
then made along the center of the cell culture area using a p200 pipette tip. The medium was then 
replaced with fresh medium containing ZOL at 0.5-10 µM or no ZOL (control). An image of the 
scratched cell monolayer was taken (“time 0”) using an inverted microscope (Nikon Eclipse 
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TS100) with a mounted digital camera (SPOT Insight QE model #4.2, SPOT Imaging Solutions, 
Michigan, USA). Cells were then grown in culture for 24 hours and another image was taken at 
the same location of the initial image. Each of the treatment conditions was done in duplicate and 
the assay results are representative of two separate experiments. 
Quantitative analysis of cell migration was done using the 24-well plate Innocyte cell 
migration assay (Calbiochem, Germany) according to the manufacturer’s directions. Briefly, 
cells were grown in culture in their respective ZOL concentrations and for various exposure 
durations and then trypsinized and washed twice with ice-cold PBS. Cells were re-suspended in 
serum free culture media to a concentration of 4-8x10
5
cells/ml. A volume of 350 µl of cells was 
added to each of the wells. For assay control, cells were incubated with 3 µM of Latrunculin A, 
an inhibitor of actin polymerization. The medium in the lower chamber contained FBS as a 
chemoattractant to induce cell migration. For control of migration cells were also incubated 
without ZOL and with and without FBS in the lower chamber (“control untreated” and “media 
w/o FBS”, respectively). Following overnight incubation the migrating cells were detached and 
labeled according to instructions of manufacturer and fluorescence was read on a FLUOstar 
Optima plate reader (BMG Labtech, Cary, NC) at 485 nm excitation and 520 nm emission. 
Quadruplicates were used for each condition and the assay was repeated twice. Results are 
reported as mean relative fluorescence units (RFU). 
 
3.8. Single cell videomicroscopy: 
 Ex vivo videomicroscopy was used for close evaluation of the effect of ZOL on survival 
and formation of tumor colonies in the lungs of mice in a model of experimental metastasis. For 
this assay, K7M2-GFP cells were grown in culture as previously described and were either left 
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untreated (“placebo”) or incubated with 10 µM ZOL for 48 hours (“Zoledronate”). Cells were 
harvested after incubation and 5x10
5
 cells were injected by tail vein to Balb/c mice (n=10 per 
cohort; placebo and zoledronate). Approximately 15 minutes after injection the mice were 
euthanized. Lungs were extracted from mice for ex vivo culture and insufflated with 1.2% low 
melting agarose and DMEM (high glucose 1x, phenol red free, sodium pyruvate free and 
glutamine free) at 1:1 concentration. Whole lungs were imaged with an inverted fluorescence 
microscope (Leica; 10x). Ten random pictures were captured per lung (n=5) per time point at 3 
and 48 hours from tumor cell injection. The mean and sum of total fluorescent area was 
quantified using Openlab software (PerkinElmer Inc., USA). 
 
3.9. In vivo experimental metastasis assay: 
 K7M2 cells were grown in culture as previously described and were either left untreated 
or were treated with ZOL at 10 µM for 48 hours. For survival analysis balb/c mice were injected 
by the tail vein with 1 x 10
6
 K7M2 cells that were either untreated (Control, n=19) or treated 
with ZOL prior to inoculation (PreZOL, n=12). Two other groups of mice was injected by the 
tail vein with untreated K7M2 cells and then treated with IP ZOL at 100 µg/kg ZOL for 5 days 
starting either on the day of inoculation (ZOL d0, n=11) or 7 days after inoculation (ZOL d7, 
n=13). Mice were monitored for signs of dehydration, decreased feed intake, weight loss and 
respiratory distress and euthanized if these were present. Kaplan-Meier survival curves were 
generated and compared between treatment groups. 
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3.10. Statistical analysis: 
 Data sets were assessed for normality using the Shapiro-Wilk test. For analysis of cell 
cytotoxicity the differences in the percentages of viable cells (double negative for Annexin V 
FITC and PI) were analyzed using a student’s t-test with a Welch correction. Differences in cell 
migration levels were analyzed using 1-ANOVA and posthoc Tukey test. Differences in vinculin 
and phalloidin fluorescence levels between treatment groups were analyzed using the Kruskal-
Wallis test and post-hoc Dunnet’s test for multiple comparisons. Differences in mean 
fluorescence in images from single cell ex vivo videomicroscopy were analyzed using a student’s 
t-test with a Welch correction. Kaplan-Meier product limit method was used for analysis of 
survival rates. A log rank test was performed to analyze statistical differences between Kaplan-
Meier curves. For all tests, a P value of less than 0.05 was considered significant. Statistical 
analysis was carried out using a commercially available software program (GraphPad InStat, 
Version 3.10). 
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CHAPTER 4 
RESULTS 
 
4.1. ZOL is not cytotoxic to K7M2 OS cells in vitro: 
 In order to verify that ZOL is not cytotoxic to K7M2 cells and to assure that it can be 
safely used in our in vitro models at intended doses we measured the induction of apoptosis after 
exposure to ZOL at 5 µM or 10 µM for 24 and 48 hours. Cell apoptosis was measured using flow 
cytometry for the markers Annexin V FITC and PI. As shown in Figure 4.1a, ZOL treatment at 
either 5 µM or 10 µM for 24 or 48 hours induced minimal increases in the levels of Annexin V 
staining when compared to untreated cells. The percentage of Annexin V positive cells was 
5.09±0.16, 5.18±0.74, and 5±38 0.56 for Control, 5 µM ZOL and 10 µM respectively after 24 
hours incubation and 3.88±0.56, 6.91±0.81, and 8.85±1.09 for Control, 5 µM ZOL and 10 µM 
respectively after 48 hours incubation (results reported as mean±SD). Results of quantification of 
Annexin V FITC and PI double negative cell percentages are shown in Figure 4.1b. These 
revealed significant differences (P < 0.01) between control and treated cells at 48 hours 
incubation. There was also a significant difference found between control and 10 µM ZOL 
treatments at 24 hours incubation (P < 0.01). Although significant, these differences were still 
regarded as being minimal and unlikely to produce a significant impact on the results of other 
assays performed in this study. 
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4.2. ZOL perturbs subcellular localization of Rho GTPases and modulates expression of p-
MLC2: 
 In order to quantify the expression levels of Rho GTPases following ZOL treatment 
K7M2 cells were either left untreated (control, 0 µM ZOL) or treated with ZOL at 5 µM or 10 
µM for 48 hours. Cell lysates from both the cytosolic and membrane fractions were subjected to 
western blot analysis to detect levels of expression of RhoA, RhoC, Cdc42 and Rac-1. As shown 
in Figure 4.2, RhoA, RhoC, Cdc42 and Rac1 showed a decrease in their expression levels in the 
membrane fraction with 10 µM of ZOL. Concurrently, there was an increase in the levels of 
expression of RhoA, RhoC and Cdc42 in the cytosolic compartment compared to control 
untreated cells. 
Graphic analysis of the expression levels of Rho GTPases for both the cytosolic and 
membrane protein fractions (Figure 4.3) supports the above findings showing decreases up to 
51% of control in the membrane protein fraction at 10 µM ZOL with concurrent increases up to 
2.6-fold of control in the cytosolic protein fraction at the same ZOL concentration. It appears that 
the shift in localization of Rho GTPases becomes visible already at 5 µM ZOL but is most 
significant when reaching 10 µM ZOL. These results emphasize the role of ZOL in inhibition of 
the mevalonate pathway and protein prenylation. 
Myosin light chain subunit 2 (MLC2) phosphorylation is regulated by ROCK activity and 
counteracted by myosin phosphatase activity. Due to its ability to inhibit myosin phosphatase, 
ROCK activity can both directly and indirectly induce increases in p-MLC2, which in turn, 
allows for improved cell motility. Based on these assumptions we characterized the expression 
levels of p-MLC2 following treatment with ZOL. We found that the levels of p-MLC2 were 
significantly reduced after treatment with ZOL at 5 µM and this finding was consistent along 4-, 
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24-, and 48-hour incubation period with ZOL (Figure 4.4a). After quantifying band signal 
strength and normalizing the expression levels of p-MLC2 to MYL9 it was found that ZOL 
treatment reduced p-MLC2 to ~40% of the expression levels in untreated cells (Figure 4.4b). 
 
4.3. ZOL negatively impacts OS cell cytoskeleton and focal adhesion complex formation: 
 To analyze the structural changes that occur in the cytoskeleton of cells after treatment 
we have exposed K7M2 cells to ZOL at 5 µM and 10 µM for 48 hours and to other inhibitor 
drugs and then used staining for phalloidin and vinculin and subjected the cells to confocal laser 
scanning immunofluorescence microscopy. The photomicrographs (Figure 4.5) revealed a 
significant decrease in phalloidin staining in ZOL-treated cells compared to untreated cells. Also, 
the staining for vinculin, representing sites of focal adhesion complexes, showed a significant 
decrease in their levels compared to untreated cells. The addition of 20 µM GGOH to ZOL-
treated cells (10 µM ZOL for 48hr) rescued the cells from the above phenotype and resulted in 
restoring of phalloidin and vinculin staining to a level similar to that in untreated cells. Treatment 
with GGTI-298 (20 µM 48hr), an inhibitor of GGTI enzyme of the mevalonate pathway, resulted 
in structural changes similar to those seen with ZOL treatment, including reduction in staining 
levels of both phalloidin and vinculin compared to untreated cells. C3 exoenzyme (RhoA/C 
inhibitor; 1 µg/ml 2hr) and Y-27632 (ROCK inhibitor; 10 µM 4hr) treatments have also resulted 
in a decreased vinculin staining, however, phalloidin showed a differential staining within the 
cell with less of it present in the cytoplasm and a stronger staining was present at the cell 
periphery comparing to treatment with ZOL and GGTI-298. 
In order to better evaluate the effect of ZOL and other inhibitors on the formation of focal 
adhesion complexes we measured fluorescence for both phalloidin and vinculin at sites of focal 
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adhesions at the cell periphery and compared these levels between treatments. The results of 
these measurements are summarized in Figure 4.6. From this analysis we were able to detect 
significant decreases in vinculin staining in ZOL-treated cells as well as with GGTI-298, C3 
exoenzyme and Y-27632 when compared to untreated cells (P < 0.001, Figure 4.6a). Similar 
changes were found when comparing phalloidin staining, however there were slightly higher 
levels of phalloidin in cells treated with C3 exoenzyme and Y-27632 compared to ZOL- and 
GGTI-298-treated cells (P < 0.001, Figure 4.6b). Cells treated with the combination of ZOL and 
GGOH had vinculin and phalloidin staining at levels not significantly different (p > 0.05) than 
untreated cells, demonstrating that GGOH can restore the effects mediated by ZOL activity. 
 
4.4. ZOL inhibits OS tumor cell migration 
 To test for ZOL’s ability to affect K7M2 cell migration we used both the scratch assay 
and a commercially available modified Boyden chamber migration assay. The results of the 
scratch assay showed that treatment with ZOL at various concentrations caused reduction in the 
ability of the cells in the monolayer to close the scratch defect whereas control untreated cells 
have covered the scratch defect completely after 24 hours from scratch formation (Figure 4.7). 
Modified Boyden chamber migration assay was used for quantitative analysis of cell 
migration in which treated and untreated cells were loaded into the chambers and let to migrate 
toward the chemoattractant (FBS). The number of successfully migrating cells was then 
quantified by measurement of fluorescence tagging according to manufacturer instructions and 
expressed as relative fluorescent units (RFU). The results of this assay (Figure 4.8) show a 
significant reduction in the levels of migrating cells when pre-treated with ZOL at either 5µM 
for 48 hours or at 10µM for either 24 or 48 hours (P < 0.001). As expected, significantly low 
59 
 
levels of cell migration were found when the chemoattractant was omitted from the destination 
chamber (P < 0.001). Similarly, treatment of cells with latrunculin A, an inhibitor of actin 
polymerization, resulted in significantly low levels of cell migration (P < 0.001). Taken 
together, both the scratch assay and the modified Boyden chamber migration assay provide 
evidence for the capability of ZOL to significantly inhibit K7M2 cell migration in vitro. 
 
4.5. ZOL reduces metastatic tumor volume and increases survival time of mice in a model of 
pulmonary metastasis 
 In this study we used ex vivo single cell video microscopy as an advanced imaging 
method for tracking of tumor cell arrest at the lung tissue and for evaluation of tumor volume in 
the lungs of mice. In this experiment we injected untreated (“Placebo”) or ZOL pre-treated 
(“Zoledronate”) K7M2-GFP cells by the tail vein to mice in a model of pulmonary metastasis.  
Tumor cell arrest and growth within the lungs was evaluated ex vivo at 3 and 48 hours from 
injection by use of fluorescence microscopy and confocal fluorescence microscopy for 
measurement of total fluorescence area and tumor volume, respectively. The pictures shown in 
Figure 4.9a show that pre-treatment of K7M2-GFP cells with ZOL resulted in a reduction in the 
fluorescent area measured at 3 hours and 48 hours from injection (“Post-injection” images). 
There were no differences in the levels of fluorescence measured before cell injection between 
untreated and ZOL-treated cells (“Pre-injection” images). Analysis of mean fluorescent area 
measurements showed significant differences in the fluorescence measured at 3 hours (P = 
0.0001) and 48 hours (P = 0.0005) between mice injected with untreated and ZOL pre-treated 
K7M2-GFP cells (Figure 4.9b). Similarly, results of sum of total fluorescence measured from 
lung samples used in the same experiment as above were found to be higher in “Placebo” group 
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when compared to “Zoledronate” group at 3 hours and 48 hours (Figure 4.9c). Interestingly, we 
were able to find that the mean and sum of total fluorescence levels decreased in lung samples 
during ex vivo culture between 3 hours and 48 hours from injection of tumor cells to the mice, 
however, the differences in fluorescence between the treatment groups still maintained. 
To evaluate the in vivo effects of ZOL we injected K7M2 cells to mice by the tail vein in 
a model of pulmonary metastasis. Mice were injected with either pre-treated (PreZOL, n=12) or 
untreated K7M2 cells. The mice injected with untreated K7M2 cells were either left untreated 
(Control, n=19) or were treated with ZOL IP starting on day 0 (ZOL d0, n=11) or on day 7 (ZOL 
d7, n=13) from cell inoculation. Comparison of Kaplan-Meier survival curves of the 4 groups of 
mice (Figure 4.10) revealed a statistically significant increase in survival times of the mice in the 
PreZOL group compared to the control group (P < 0.03). Intra-peritoneal ZOL treatment in both 
regimens (ZOL d0 and ZOL d7) had no significant effect on survival time of mice when 
comparing to the control group. 
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CHAPTER 5 
DISCUSSION AND CONCLUSIONS 
 
In this study we present data to support that ZOL inhibits OS tumor cell migration and 
metastasis through perturbations in the sub-cellular localization of Rho GTPases attributed to 
inhibition of protein prenylation. These changes elicited disorganization of the cell cytoskeleton 
with a decrease in the levels of focal adhesions and actin stress fibers. 
It has been previously described that Rho GTPases are overexpressed in multiple types of 
cancer diseases [207] and that these proteins have a crucial role in directional motility and in the 
“migratory cycle” of cancer cells [14, 208]. In our study, we showed that treatment with ZOL 
changes the subcellular localization of Rho GTPases and reduces their expression level at the 
membrane fraction. These results correlate well with previous studies showing that nitrogen-
containing bisphosphonates inhibit the enzymes of the mevalonate pathway resulting in reduced 
protein prenylation [238]. 
One of the surrogate markers for the functionality of Rho/ROCK pathway is the 
phosphorylation status of myosin light chain protein. In our study, we found that indeed, 
following treatment with ZOL there was a significant decrease in the phosphorylation of MLC2, 
correlating with reduced expression of RhoA and RhoC at the membrane fraction. It has been 
shown that increases in p-MLC2 expression correlate with cancer cell protrusion and 
invasiveness [221], assembly of stress fibers and focal adhesions [15], and cell polarization and 
migration [270]. It is likely that the decrease in the expression of p-MLC2 found in our study 
results in a less invasive OS cell phenotype, which may correlate with reduced metastatic 
properties. 
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The results of immunofluorescence microscopy in our study give further support for a 
change in the phenotype of K7M2 cells induced by ZOL. These showed significant reductions in 
the levels of cytoskeletal F-actin and peripheral focal adhesion complexes after treatment with 
ZOL. Similar patterns of reduced staining were seen with the use of GGTI-298, an inhibitor of 
the mevalonate pathway GGTase I enzyme. Also, the addition of GGOH to ZOL-treated cells 
reversed this effect, enforcing the conclusion that these changes are caused by inhibition of 
protein prenylation. This loss of cell cytoskeleton integrity likely has a detrimental effect on 
many cellular functions since it is important for communication with ECM, inside-out and 
outside-in signal transduction pathways and growth control [135, 271]. It is known that intact 
cytoskeleton is also necessary for cell protrusion by actin polymerization and by actomyosin-
mediated contraction [272], and there is evidence linking Rho GTPase activity to activation of 
actomyosin system for migration and invasion [195, 273] and formation of stress fibers and focal 
adhesion complexes [274]. Based on this, we attribute the cytoskeletal changes seen after 
treatment with ZOL to inhibition of the mevalonate pathway and perturbation of the sub-cellular 
localization and activity of Rho GTPases. 
Associating with the changes found in the cell cytoskeleton, we show that the migration 
ability of OS cells was greatly diminished after treatment with ZOL. Previous reports show 
involvement of Rho GTPases in different aspects of rearrangement of the cell cytoskeleton for 
migration. Cdc42 and Rac1 are mainly active at the leading edge of the cell where they control 
polarization towards the direction of movement, extension of cell protrusions, and formation of 
focal adhesion complexes for cell-matrix interaction [14, 209]. RhoA and RhoC are active 
mainly at the rear end of migrating cells, promoting cell detachment by contraction of actin stress 
fibers and loosening of focal adhesions [14]; these functions are mediated by RhoA/RhoC 
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effectors, Rho-kinase I and II (ROCK I/II) [219]. Remarkably, retroviral knockdown of RhoC 
was able to inhibit invasion and metastasis of human hepatocellular carcinoma in both in vitro 
and in vivo models [254]. Likewise, the reduction in expression of Rho GTPases seen in our 
study likely leads to reduced activity of these proteins and their effector molecules with 
subsequent disorganization of cytoskeletal elements. This severe impairment is likely to be the 
cause for the reduced migration capacity found after treatment with ZOL and is another evidence 
for reduced level of invasiveness in ZOL-treated K7M2 cells. 
The results from ex vivo videomicroscopy clearly support an anti-metastatic role for ZOL 
since the pre-treatment of K7M2 cells with ZOL caused a significant reduction in the numbers of 
cells that were able to arrest at 3 hours in the lungs of mice. This may be reflecting an impact of 
ZOL on the early steps necessary in the metastatic cascade, including extravasation from the 
blood circulation and invasion/migration into the lung tissue. Despite these steps being very 
efficient in the cascade [5, 6], we estimate that in vitro pre-treatment of tumor cells with ZOL 
prior to injection to mice in our model of experimental metastasis was strong enough to allow for 
detection of this early effect.  
It is also possible that treatment with ZOL increases the metastatic inefficiency of K7M2 
cells by affecting the events that occur post-extravasation at the secondary site, a phase in which 
tumor cells must exhibit a capacity for directional mobility that is dependent upon changes in 
cell morphology, as well as ECM remodeling [90, 275, 276]. Rho GTPase activity for formation 
of focal adhesion complexes plays a significant role in integrin signaling cascades that control 
post-extravasation cell locomotion for tissue migration and invasion [138, 277]. It is probable 
that changes in sub-cellular localization and activity of Rho-GTPases is responsible for 
perturbation of these signaling pathways, resulting in metastatic inefficiency. 
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Further, results from our ex vivo videomicroscopy experiment showed a significant 
reduction in outgrowth and formation of micrometastatic disease in the lungs of mice at 48 hours 
from cell injection. Interestingly, the mean and sum of total fluorescence levels reduced between 
3 and 48 hours in both groups, demonstrating a selection towards cells able to survive in the pre-
metastatic niche and able to start formation of micrometastatic tumor colonies. We believe that 
the differences seen in levels of fluorescence between treatment groups are a direct consequence 
of the earlier effects of ZOL pre-treatment seen at 3 hours from injection and that the reduced 
arrest of tumor cells in the lung translated to lower numbers of cells able to establish tumor 
colonies.  
Other than a direct impact on the number of cells able to outgrow in the lung, we also 
hypothesize that impairment of Rho GTPase activity may induce anoikis sensitivity in the tumor 
cells. It was previously shown that integrin signaling through Rho GTPases is linked to anoikis 
resistance and activation of AKT/PKB survival pathway [197, 228] which has a significant role 
in determination of endurance of the cell at the secondary site [278]. The loss of these functions, 
elicited by treatment with ZOL, must play a significant role in the survivability of individual 
tumor cells after they arrive at the new environment, likely leading to inhibition and/or delay of 
establishment and growth of lung nodules.  
In our study we were also able to show that treatment of K7M2 cells with ZOL increased 
the survival time of mice in a model of pulmonary metastasis. However, although the difference 
in survival time was found to be statistically significant when compared to untreated mice, it did 
not improve the outcome considerably. One possible explanation for this is the design chosen for 
modeling of lung metastasis in our study. Tail vein injection of tumor cells in mice results in an 
extreme amount of cells showering the lungs; an amount that is non-physiological and 
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significantly higher than what is found in naturally occurring tumors. Even with the microscopic 
evidence of the effects of ZOL pre-treatment in our ex vivo videomicroscopy experiments we 
believe that these effects are likely lost with time in our in vivo survival model since the 
propensity for lung nodule formation is still relatively high and successful tumor colonies may 
still give rise to secondary metastasis from one area within the lung to another.  
Interestingly, the increase in mice survival following tail vein injection of the tumor cells 
was found only when these were pre-treated in vitro with ZOL prior to injection; treatment of 
mice with ZOL IP after injection of untreated cells did not result in the same survival benefit. We 
believe that this outcome is the result of the loss of “window of opportunity” for ZOL to make its 
effect on the tumor cells; once tumor cells are injected and arrive at the metastatic niche within 
the lung parenchyma they quickly establish themselves and start forming tumor colonies prior to 
being affected by ZOL treatment when given IP. Also, it is known that ZOL concentrates mostly 
in bone matrix and reaches lower concentrations for shorter time periods in visceral organs 
[279]. It is likely that in vitro treatment with ZOL allows for significant intracellular cytoskeletal 
modulation and impairment of integrin-related and other signaling pathways through inhibition 
of Rho GTPases, much more than that allowed with IP treatment, and that this led to the 
observed outcome 
Although the results of our in vivo model for experimental metastasis showed only minor 
increases in survival times of mice injected with ZOL pre-treated cells we believe that ZOL may 
still be beneficial as an anti-metastatic agent as it may have a superior impact on migration and 
survival of cancer cells in patients with naturally occurring tumors. There is increasing evidence 
that cancer stem cells (CSCs) have an important role in metastasis in various types of tumors [2, 
82-84]. Notably, there is specific evidence that supports the presence of bone-marrow derived 
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DTCs that have cancer stem cell characteristics in human breast cancer patients [82] and that the 
presence of these cells is a poor prognostic indicator [280, 281]. It was also found that CSCs 
disseminate from the periphery of the primary tumors in pancreatic carcinoma [2], and other 
lines of evidence led to the theory of migrating cancer stem cells being responsible for primary 
mass growth and distant metastasis in colon cancer [3]. Interestingly, clinical trials support a 
positive anti-metastatic effect for treatment with BPs against breast cancer patients [282], and 
ZOL treatment caused a significant reduction in levels of DTCs in clinically affected patients 
[283]. This evidence, together with the results of our study leads us to suggest that ZOL may also 
have the capability to reduce dissemination of OS tumor cells from the primary bone tumor to 
distant sites given its in vitro effects and preferential concentration in remodeled bone matrix.  It 
is also possible that ZOL may allow reduction of secondary metastasis from existing lung 
nodules to other locations within the lung and/or other tertiary sites.  
This study has a few limitations. First, the study focuses on the effects of ZOL in one cell 
line only. Although tested in vivo in a compatible murine model of pulmonary metastasis, our 
results are limited only to this model and may not reflect outcomes in other tumor types. Also, as 
discussed above, the conclusions from our ex vivo and in vivo experiments are limited to the 
experimental model we used for lung metastasis which may not reflect outcomes with naturally 
occurring tumors. Another limitation of this study is related to the fact that inhibition of FTase 
synthase by ZOL may not only impair the activity of RhoA, RhoC, Cdc42 and Rac1 but also 
other small GTPases and other proteins that require prenylation for normal function. It is 
possible, therefore, that there are other mechanisms and causes for the results found here and that 
these may not be solely related to the activity of the Rho GTPases we investigated. Lastly, Rho 
GTPases are involved not only in many aspects of tumorigenesis but also in a variety of cell 
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functions including apoptosis/anoikis, cell cycle and angiogenesis. Hence, impairment of Rho 
GTPases activity unlikely causes only derangement in tumor cell cytoskeleton but also affects 
cell death/quiescence and may induce changes in the tumor microenvironment such that would 
arrest further tumor progression. Further investigation of the molecular pathways that are 
perturbed by ZOL’s activity is necessary to obtain better understanding of the mechanisms of its 
action. Additionally, investigation of the effects of ZOL as adjuvant to chemotherapy is also 
important since induction of anoikis sensitivity may allow for synergism between the two agents 
and may provide an improvement in survival times when compared to outcomes with 
chemotherapy alone. 
In conclusion, our data shows that ZOL induces changes in the subcellular localization 
pattern of Rho GTPases attributed to inhibition of the mevalonate pathway, with subsequent loss 
of integrity of the cell cytoskeleton and reduced cell migration. Treatment with ZOL also 
resulted in early reduction in pulmonary nodule formation and a modest but significant increased 
survival time in mice with lung metastasis. These findings suggest that ZOL has anti-metastatic 
capacities in murine OS cells. Investigation of the effects of ZOL when used in conjunction with 
chemotherapy on OS cells may prove to be beneficial as ZOL may sensitize the tumor cells to 
anoikis. 
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CHAPTER 6 
FIGURES 
Figure 2.1.  Models for the metastatic capability of the primary tumor. (a) The “progression 
model”: rare cells of the primary tumor are able to metastasize and escape to form a distant 
nodule. (b) The “early oncogenesis model”: primary tumors have either a good-(pink) or poor-
(red) prognosis signature that can be predicted at an early tumor stage. Poor prognosis signature 
leads to formation of metastasis. (c) Model by Kang et al.: metastatic tumors have a poor 
prognosis signature superimposed by a tissue-specific expression profile (green, yellow and blue 
depict different organs). (Van't Veer et al., Nature Medicine 9(8), 999-1000, 2003). 
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Figure 2.2. Colon cancer progression and MCS cells. A crucial step for malignancy is the 
induction of EMT and transition of stationary CSC to become mobile MCS cells initially 
localized at the tumor-host interface. (A) MCS cells divide asymmetrically and make primary 
tumor. (B) Short distance migration adds cells to primary tumor. (c) Long distance migration 
leads to metastasis. (Brabletz et al., Nature Reviews Cancer 5, 744-9, September 2005). 
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Figure 2.3. An integrative model of breast cancer. Mutations may occur in a stem cell (red) and 
lead to poor-prognosis signature and CSCs spread to various tissues (for instance: green, bone; 
purple, lung). Mutations in a differentiated progenitor cell have a good-signature prognosis 
(pink). (Weigelt et al., Nature Reviews Cancer 5, 591-602, August 2005). 
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Figure 2.4. The main steps in formation of metastases. All of the steps must be completed 
sequentially for the successful formation of a distant tumor nodule. (Fidler et al., Nature Reviews 
Cancer 3, 453-8, June 2003). 
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Figure 2.5. EMT signaling pathways in embryonic development and human pathologies. Tissue 
targets are noted under each of the inducers. (Thiery et al., Cell 139, 871-890, November 2009). 
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Figure 2.6. The steps in cell migration and the regulators involved in each step (Ridley et al., 
Science 302, 1704-1709, December 2003). 
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Figure 2.7. The different actin-based structures associated with cancer cell migration/invasion. 
White arrows point the direction of cell migration. (Olson M.F. & E. Sahai, Clin Exp Metastasis 
26, 273-287, May 2008). 
 
 
 
Figure 2.8. Signal transduction pathways induced by integrins (Eble J.A. & J. Haier, Curr 
Cancer Drug Targets 6(2), 82-105, March 2006). 
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Figure 2.9. Regulation of Rho GTPase activity (Etienne-Manneville S. & A. Hall, Nature 420, 
629-636, December 2002). 
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Figure 2.10. Regulation of Rho GTPase homeostasis by RhoGDI. Red arrows indicate partly 
folded or misfolded intermediates. Other than RhoGDI, Hsp70 also acts as a chaperone for Rho 
GTPases (Boulter E. & P.M. Gullino, Nature Cell Biology 12(5), 477-483, May 2010). 
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Figure 2.11. Biosynthesis of isoprenoids through the mevalonate pathway. Farnesyl 
pyrophosphate (FPP) is used for farnesylation of Ras proteins and geranylgeranyl pyrophosphate 
(GGPP) is used for geranylgeranylation of Rho GTPases (Konstantinopoulos P.A. et al., Nature 
Reviews Drug Discovery 6, 541-555, July 2007). 
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Figure 2.12. Protein isoprenylation and post prenylation reactions (Jakobisiak M. and J. Golab, 
Med Res Rev 30(1), 102-135, January 2010). 
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Figure 2.13. Tumor-related functions of Rho GTPases from in vitro studies (Karlsson R. et al., 
Biochim Biophys Acta 1796(2), 91-98, March 2009). 
 
 
 
Figure 2.14. Signaling from Rho to the cytoskeleton (Burridge K. & K. Wennerberg, Cell 116(2), 
167-179, January 2004). 
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Figure 2.15. Formation of filopodia and lamellipodia. a. A schematic image showing the 
structure of filopodia and lamellipodia and the proteins involved in their production. b. Cdc42 
and Rac effectors controlling production of filopodia and lamellipodia (Heasman S.J. & A.J. 
Ridley, Nature Rev Mol Cell Biol 9(9), 690-701, September 2008). 
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Figure 2.16. The mevalonate pathway and sites of inhibition by statins, bisphosphonates and 
other inhibitors (Roelofs A.J. et al., Clin Cancer Res 12(20 Suppl), 6222-6230, October 2006). 
 
 
 
Figure 2.17. Zoledronate chemical structure (http://en.wikipedia.org/wiki/File:Zoledronic_ 
acid.svg) 
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Figure 4.1a. Effect of ZOL treatment on K7M2 cell apoptosis. Cells were either left untreated 
(Control) or incubated with 5 µM or 10 µM for 24 and 48 hours. Flow cytometry was used for 
measurement of PI and Annexin V FITC staining. ZOL treatment induced minimal levels of 
apoptosis when compared to untreated cells. Images are representative of 3 separate experiments.
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Figure 4.1b. Effect of ZOL treatment on K7M2 cell apoptosis. The bar graph demonstrates the 
levels of double negative cells after flow cytometry for Annexin V FITC and PI (representative 
of intact cells). Although significant differences were found between control and treatment 
conditions at 24 hours and 48 hours incubation the overall reductions were considered minimal 
and of low likelihood to affect results of other in vitro assays (* P < 0.01). 
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Figure 4.2. Effect of ZOL treatment on the expression levels of Rho GTPases in the membrane 
and cytosolic cell compartment. Treatment with 10 µM ZOL resulted in reduction in the 
membrane expression of Rho GTPases with a concurrent increase in the cytosolic expression. 
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Figure 4.3. Graphic analysis of the expression levels of Rho GTPases in (a) cytosolic and (b) 
membrane protein fractions following treatment with ZOL. The results show increases up to 2.6-
fold of control expression in the cytosolic fraction and reductions up to 51% of control 
expression in the membrane fraction. 
 
b 
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Figure 4.4. Effect of ZOL treatment on the expression levels of p-MLC2. Treatment with ZOL at 
the stated concentrations and incubation periods resulted in (a) reduction in the expression of p-
MLC compared to expression levels of MYL9 and (b) reductions down to 40% of control levels 
were visible in the ratio of p-MLC2/MYL9 after treatment. 
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Figure 4.5. Immunofluorescence microscopy for cell cytoskeletal elements. Cells were treated 
with ZOL and other inhibitors as indicated above and stained with immunofluorescent antibodies 
for vinculin and phalloidin. Cells treated with ZOL showed reductions in F-actin and focal 
adhesions while addition of GGOH to ZOL-treated cells reversed this effect. 
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Figure 4.5 (Cont.). Immunofluorescence microscopy for cell cytoskeletal elements. Cells treated 
with GGTI-298, C3 exo and Y-27632 showed reductions in F-actin and focal adhesions. 
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Figure 4.6a. Pixel quantification of vinculin immunfluorescence at sites of focal adhesion 
complexes. Median fluorescence was measured at sites of focal adhesion complexes in each of 
the treatments and expressed as percent of control. The results show significant decreases in 
vinculin staining after treatment with ZOL at 5 µM and 10 µM (* P < 0.001). 
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Figure 4.6b. Pixel quantification of phalloidin immunfluorescence at sites of focal adhesion 
complexes. Median fluorescence was measured at sites of focal adhesion complexes in each of 
the treatments and expressed as percent of control. The results show significant decreases in 
vinculin and phalloidin staining after treatment with ZOL at 5 µM and 10 µM (* P < 0.001). 
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Figure 4.7. Treatment with ZOL inhibits cell migration in a scratch assay. A monolayer of K7M2 
cells was scratched and cells were then treated with ZOL at indicated concentrations. Coverage 
of defect by cells was documented by photomicrographs after 24hr period of incubation. 
Treatment with ZOL inhibited “scratch healing” even at very low drug concentrations but the 
effect was subjectively more pronounced with 5 µM and 10 µM ZOL. Images are representative 
of 2 separate experiments. 
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Figure 4.8. ZOL inhibits K7M2 cell migration in a modified Boyden chamber migration assay. 
K7M2 cells were treated as indicated and loaded into chambers for migration towards a 
chemoattractant (FBS). Successfully migrating cells were tagged with a fluorescent marker and 
then quantified. Levels of fluorescence are expressed as relative fluorescence units (RFU). 
Latrunculin A was used as control for inhibition of cell migration and media without FBS was 
used as a negative control for cell migration. The results show a significant decrease in cell 
migration after treatment with ZOL when compared to migration of untreated cells (* P < 
0.001). 
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Figure 4.9a. ZOL inhibits OS tumor cell growth and expansion in a mouse model of pulmonary 
metastasis. Results of ex vivo single cell video microscopy show reduction in levels of 
fluorescence in lungs of mice injected with ZOL pre-treated cells (“Zoledonate”; 10 µM for 48 
hours) compared to injection with untreated cells (“Placebo”) at 3 and 48 hours after injection 
(“Post-injection” pictures). Pictures of K7M2-GFP cells before injection (“Pre-injection”) show 
no difference in cell fluorescence between Zoledronate and Placebo groups. 
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Figure 4.9b. Mean fluorescence area measured ex vivo in lung samples (n=5) of mice injected 
with untreated (“Placebo”) or ZOL pre-treated (“Zoledronate”; 10 µM for 48 hours) K7M2-GFP 
cells. Pre-treatment of cells with ZOL resulted in a significant reduction in the mean fluorescent 
area at 3 hours (* P = 0.0001) and 48 hours († P = 0.0005) when compared to results in the 
“Placebo” group. 
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Figure 4.9c. Sum of total fluorescence area measured ex vivo in lung samples (n=5) of mice 
injected with untreated (“Placebo”) or ZOL pre-treated (“Zoledronate”; 10 µM for 48 hours) 
K7M2-GFP cells. Pre-treatment of cells with ZOL resulted in a reduction in the total fluorescent 
area at 3 hours and 48 hours when compared to results in the “Placebo” group. 
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Figure 4.10. ZOL in vitro pre-treatment modestly but significantly increased survival of mice in 
a model of experimental lung metastasis. Balb/c mice were injected by the tail vein with treated 
(PreZOL) or untreated (control) K7M2 cells. Additionally, two groups of mice that were injected 
with untreated K7M2 cells were treated with ZOL IP (ZOL d0 and ZOL d7). Median survival 
time (MST) for control, ZOL d0 and ZOL d7 mice was similar at 18 days.  MST for PreZOL 
group was modestly increased to 20 days. The Kaplan-Meier curves show a statistically 
significant increase in survival time in the PreZOL group compared to all other groups (P < 
0.03). 
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